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Abstract 
Latent infections with the human pathogenic microorganisms Mycobacterium tuber-
culosis (Mtb) and the human immunodeficiency virus (HIV) are creating some of the 
most devastating pandemics to date, with great impact on the infected people’s lives, 
their expected lifetime, as well as general costs for society. Consequently there is a 
pressing need to search for new treatment strategies. Nowadays it is known that HIV-
1 and Mtb have acquired the ability to escape the removal from the body by exploit-
ing the immune system for their own benefits. Dendritic cells (DCs) determine the 
way the immune response unfolds by signaling other immune cells how to respond. 
An early deregulation of the DCs may therefore propagate into detrimental effects in 
later stages of the immune response, and may permit HIV-1 and Mtb to become la-
tent. Hence, understanding the way HIV-1 and Mtb interacts with DCs could lead to 
novel treatment strategies. In the present work this has been examined in purified hu-
man plasmacytoid DCs (pDCs) and monocyte-derived DCs (moDCs). First it is 
demonstrated how Mtb exploits plasticity in moDCs to avoid production of the cyto-
kine IL-12p70 necessary for protection against Mtb. Then it is shown that Mtb induc-
es signaling in moDCs that misdirects the immune response into an extracellular Th17 
response, even though the bacteria hide inside immune cells. Finally it is demonstrat-
ed how HIV-1 strains, capable of provoking sustained infection, induce a high-
mannose-independent complete necrotic eradication of the pDCs that is needed to 
inhibit initial infection. The results presented in this thesis provide novel insights into 
immune evasion strategies employed by HIV-1 and Mtb. These findings could even-
tually be utilized for better treatment strategies against AIDS and tuberculosis disease 
when specific strategies for immune cell perturbations are established.  
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Dansk Resumé 
Latente infektioner med de humane patogene mikroorganismer Mycobacterium tuber-
culosis (Mtb) og human immundefekt virus (HIV) har skabt nogle af de største pan-
demier til dato, og har stor indflydelse på de inficerede menneskers liv, deres forven-
tede levetid, samt generelle omkostninger for samfundet. Derfor er der et presserende 
behov for at søge efter nye behandlingsstrategier. I dag er det kendt, at HIV-1 og Mtb 
har erhvervet evnen til at undslippe fjernelse fra kroppen ved at udnytte immunre-
sponset til deres egne fordele. Dendritiske celler (DCer) er afgørende for hvordan 
immunresponset propagerer ved at signalere til andre immunceller, hvordan de skal 
respondere. En tidlig deregulering af DCerne kan derfor føre til skadelige virkninger i 
senere faser af immunresponset, og dermed betyde at HIV-1 og Mtb bliver latente. 
Derfor kan en bedre forståelse af måden hvorpå HIV-1 og Mtb interagerer med DCer 
føre til hidtil ukendte behandlingsstrategier. I det foreliggende arbejde er dette blevet 
undersøgt i oprensede humane plasmacytoide DCer (pDCer) og monocyt-afledte 
DCer (moDCer). Først beskrives hvordan Mtb kan udnytte plasticiteten af moDCer til 
at forhindre produktion af cytokinet IL-12p70, der ellers er nødvendig for at beskytte 
mod Mtb. Derefter demonstreres det, at Mtb inducerer signalering i moDCer som 
medierer et ekstracellulært Th17 respons, selv om bakterien gemmer sig indeni im-
munceller. Endelig er det vist hvordan HIV-1-stammer, der er i stand til at fremtvinge 
en vedvarende infektion, inducerer en mannose-uafhængig komplet nekrotisk udryd-
delse af pDCer, som ellers er nødvendige for at inhibere tidlig infektion. Resultaterne 
der præsenteres i denne afhandling giver ny indsigt i immunevasionsstrategier som 
HIV-1 og Mtb benytter. Disse resultater kan på lang sigt anvendes til bedre behand-
lingsstrategier mod AIDS og tuberkulose, når specifikke strategier for immuncelle-
perturbering er etableret. 
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Abbreviation Full name 
Ag  antigen 
AIDS acquired immunodeficiency syndrome 
AIM2  absent in melanoma 2 
ASC apoptosis-associated speck-like protein containing 
 
 a CARD (caspase-recruitment domain) 
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ERK extracellular-signal-regulated kinase 
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hi high 
HIV human immunodeficiency virus 
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IRAK-M interleukin-1 receptor-associated kinase 3 
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JNK c-Jun N-terminal kinase 
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MDA5 melanoma-differentiation-associated gene 5 
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MDP muramyldipeptid 
MDR multidrug resistant 
MEK mitogen activated protein kinase/ERK kinase 
MFI  mean fluorescence intensity 
MHC major histocompatibility complex 
moDC monocyte-derived dendritic cell 
MOI multiplicity of infection 
MR mannose receptor (CD206) 
Mtb M. tuberculosis 
MyD88 myeloid differentiation primary-response gene 88 
NALP NACHT-, LRR- and pyrin-domain-containing protein 
NF-"B nuclear factor-"B 
NK natural killer 
NOD nucleotide oligomerization domain 
PAMP Pathogen-associated molecular patterns 
PBMC peripheral blood mononuclear cell 
PD-L1 programmed cell death 1 ligand 1 (CD274)  
pDC plasmacytoid dendritic cell 
PGN peptidoglycan 
PI3K phosphatidylinositol 3-kinase 
PIM phosphatidylinositol mannosides 
PRR pattern recognition receptors 
R5 CCR5 tropic 
RA retinoic acid 
RICK receptor-interacting serine/threonine kinase 
RIG-I retinoic acid-inducible gene I 
ROR!T RAR-related orphan receptor !T 
SIV simian immunodeficiency virus 
ss single-stranded 
STING  stimulator of interferon genes 
 xi 
SYK  spleen tyrosine kinase 
T-bet T-box transcription factor TBX21 
TB tuberculosis 
TBK1 TANK-binding kinase 1 
TCR T cell receptor 
TGF transforming growth factor 
Th T helper 1 
TIRAP Toll/IL-1R (TIR)-domain-containing adaptor protein 
TLE transducin-like enhancer of split 
TLR toll-like receptor 
TNF tumor necrosis factor 
TRAF TNF receptor associated factor. 
TRAIL TNF-related apoptosis-inducing ligand 
TRAM TRIF-related adaptor molecule 
Treg Regulatory T cell 
TRIF TIR-domain-containing adaptor protein inducing IFN# 
X4 CXCR4 tropic 
XDR extensively drug resistant 
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1 Introduction 
1.1 The latency-instigating pathogens: M. tuberculosis and HIV 
Latent infections are a major threat to the global human health. The two most notori-
ous pathogens causing latent infections are the human immunodeficiency virus (HIV) 
and Mycobacterium tuberculosis (Mtb). HIV-1 is the causative agent for the disease 
called acquired immunodeficiency syndrome (AIDS) and Mtb is the causative agent 
for the disease tuberculosis (TB). Approximately 34 million people are currently in-
fected with HIV-1 and around one third of the world’s population is infected with 
Mtb.1,2 Each year 1.5-2 million people die from each of these infections (Fig. 1.1). 
The combined infection with both these pathogens is especially dangerous, as HIV-1 
thrives of the immune cells that help inhibiting active TB. People having both infec-
tions are 21-34 times more likely to develop TB compared to people who are HIV-1-
negative.3 Some treatments for controlling development of AIDS and TB already ex-
ist. There is currently no vaccine against HIV-infection, however, once infected there 
are drugs capable of increasing HIV-positive patients’ life expectancy by on average 
13 years.4 These drugs are called highly active antiretroviral therapy (HAART) and 
consist of three or more different drugs targeting reverse transcription and protease 
activity.5 In this sense, HAART does not affect previously infected cells, but can ef-
fectively inhibit productive infection of new cells. In contrast to HIV-1, a vaccine 
against Mtb infection does exist. The Bacille Calmette-Guérin (BCG) vaccine was 
discovered in 1921 and consists of an attenuated bovine tuberculosis strain.6 The 
problem with this vaccine is that it does not consistently prevent Mtb infection. In 
some trials it works (80% protection, Haiti trial, n = 3,1007) and in others it does not 
work at all (0% protection, India trial, n = 350,0008). If a person has become infected 
with a traditional non-drug-resistant Mtb strain, multidrug therapy for 9 months can 
clear the infection.9 The eradication of one Mtb infection, however, does not protect 
against re-infection, and multidrug resistant (MDR) and extensively drug resistant 
(XDR) strains have also developed. MDR requires two years of antibiotic treatment 
and XDR is often untreatable and fatal.10 Consequently, sufficient treatments against 
HIV-1 and Mtb do not exist, and the need for new treatment strategies is in high de-
mand. 
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Fig. 1.1: Number of annual deaths caused by the acquired immunodeficiency syndrome and tu-
berculosis. A) The number of annual deaths caused by acquired immunodeficiency syndrome (AIDS) 
(brown line), number of people living with human immunodeficiency virus (HIV)-1 (blue bars), and 
number of people newly infected with HIV-1 (red line). B) Number of M. tuberculosis (Mtb)-infected 
people and annual deaths caused by tuberculosis (TB).11–13 
 
Common for HIV-1 and Mtb is an exploitation of the immune system for their surviv-
al. They both mount an active immune response, but somehow the induced immune 
response is not sufficient, indicating that they both harbor immune-diverting abilities. 
In a manner similar to the Butterfly Effect,14 the early events upon infection play an 
utmost important role for the progression of the immune response.15,16 At the earliest 
A)
B)
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stage of immune activation dendritic cells (DCs) play a pivotal part. DCs are a heter-
ogeneous population of cells, with the common attribute to initiate and regulate im-
mune responses. They recognize when an infection has occurred, and subsequently 
convey the information to other immune cells including, but not limited to, naïve T 
cells.17 Naïve T cells are pluripotent and can differentiate along different pathways to 
become distinct effector cells, depending on the additional signals received during 
activation. Therefore, dependent on the signals provided by the DCs, the immune sys-
tem can react in many different ways. Pathogen-associated molecular patterns 
(PAMPs) are the basis for recognition of foreign intruders. PAMPs are conserved 
structures that do not resemble other structures found in the human host, and are typi-
cally essential components of microbial structure. The receptors on human immune 
cells that recognize these conserved patterns are called pattern recognition receptors 
(PRRs). Pathogens often uses mutations to avoid immune recognition, but the ingen-
iousness behind PRRs is that they recognize patterns that cannot be mutated, as they 
are essential for the pathogenicity or survival of the microorganisms. There are a 
range of PRR categories, with the most prominent being the toll-like receptors 
(TLRs), nucleotide oligomerization domain (NOD)-like receptors, retinoic acid-
inducible gene I (RIG-I)-like receptors, and C-type lectin receptors (CLRs) (Fig. 1.2). 
Triggering of these receptors induces activation of transcription factors including nu-
clear factor-!B (NF-!B) and interferon regulatory factors (IRFs) eventually leading to 
release of cytokines, chemokines and interferons (IFNs) and up-regulation of accesso-
ry molecules required for efficient stimulation of T cell responses necessary for path-
ogen clearance (Fig. 1.2). 
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Fig. 1.2: Overview of pathogen recognizing receptors. Toll like receptors (TLRs) are found both as 
membrane-bound extracellular receptors (TLR1, 2, 4-6), and as endosomal receptors (TLR3, 7-9). The 
retinoic acid-inducible gene I (RIG-I)-like receptors: RIG-I and MDA5 (melanoma-differentiation-
associated gene 5), and the nucleotide oligomerization domain (NOD)-like receptors: NOD1/2 and 
NALP (NACHT-, LRR- and pyrin-domain-containing protein) are all cytosolic receptors. C-type lectin 
receptors like Dectin-1 are membrane-bound. Dependent on cellular location and affinity for different 
structures, these different pattern recognizing receptors (PRRs) recognize different pathogen associated 
molecular patterns (PAMPs) such as lipoproteins, lipopolysaccharide (LPS), single-stranded (ss)RNA, 
double-stranded (ds)RNA, DNA, and glycans. Ligation induces a complex series of signaling, and only 
specific key molecules like nuclear factor "B (NF-"B) is shown on the figure. ASC, apoptosis-
associated speck-like protein containing a CARD (caspase-recruitment domain); IFN, interferon; I"B, 
inhibitor of NF-"B; IL, interleukin; IPAF, ICE-protease-activating factor; IRF, IFN-regulatory factor; 
MyD88, myeloid differentiation primary-response gene 88; RICK, receptor-interacting serine/threonine 
kinase; TBK1, TANK-binding kinase 1; TIRAP, Toll/IL-1R (TIR)-domain-containing adaptor protein; 
TRAM, TRIF-related adaptor molecule; TRIF, TIR-domain-containing adaptor protein inducing IFN-
#; SYK, spleen tyrosine kinase.18 
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Accumulating evidence suggests that HIV-1 and Mtb, harbor the capacity to escape 
immune recognition by circumventing the positive signals induced by PRR recogni-
tion due to negative regulation of TLR signaling.19–26 Concurrent with TLR-binding 
of certain PAMPs, other ligands from the same microbe interact with regulatory re-
ceptors leading to polarization of the immune response towards tolerance. The ligands 
being able to induce this negative cross-regulation are primarily glycan-moieties dis-
played on the surface of pathogenic microbes interacting with CLRs. In this way 
CLRs play a dual role in the immune system, both being important in antigen uptake 
and at the same time being able to induce an immunomodulatory effect. However, not 
only CLR-triggering could divert the immune response away from a productive re-
sponse. Triggering of some TLRs may inhibit pathways induced by other TLRs,27,28 
adding to the complexity of the pathogen-induced immune regulation. 
 
Because of a different PAMP expression and localization of the infections, the specif-
ic PRRs, and cell types recognizing HIV-1 and Mtb are different. Therefore the de-
scription of interaction between these pathogens and the immune system has been 
divided into two different sections. Chapter 1.2-1.5 describes the immune recognition 
of Mtb, while chapter 1.8-1.11 describes the recognition of HIV-1. Chapters 1.7 and 
1.12 describe the motivation for the studies conducted in this Ph.D. thesis.   
 
1.2 The host response to Mtb 
Mtb is spread through aerosols and enters the body through the lungs. Characteristic 
for the immune response against Mtb is the development of a granuloma in the lungs, 
consisting of an aggregate of various lymphocytes (Fig. 1.3). This limits bacterial 
spread, but also limits interaction of immune cells with infected cells after the granu-
loma has formed. Active disease evolves when bacteria spread to other sites of the 
body. This can for instance happen when the immune system is dampened, e.g. by 
virtue of an HIV-1 infection mediating a cytopathic effect on CD4+ T cells,29–32 or 
when patients receive immune dampening medicine like anti-tumor necrosis factor 
(TNF)-$ to treat rheumatoid arthritis and Crohn’s disease.33  
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Fig. 1.3: Schematic representation of the granuloma. A granuloma is an aggregate of immune cells 
shielding off Mtb from the rest of the body. In the middle of the granuloma is often found a caseous-
like substance consisting of dead and necrotic lymphocytes. Inside the granuloma Mtb can be found 
both extracellularly and intracellularly in macrophages. NK, natural killer.34 
  
The first cells Mtb interacts with are the alveolar macrophages and myeloid DCs 
(mDCs).35–37 Normally when microorganisms are taken up by macrophages they are 
degraded in the lysosomal compartment.38,39 Mtb, however, has developed a tech-
nique to divert this by inhibiting fusion of the phagosomes with the lysosomes, and by 
inhibiting autophagy.40 Unlike macrophages, Mtb is not able to grow inside mDCs.41 
Upon uptake of Mtb, mDCs migrate to the draining lymph nodes.35,37 Here they inter-
act with naïve T cells, presenting Mtb-derived antigen (Ag) and providing co-
stimulatory and differentiation signals for the T cells.42 After maturation the T cells 
migrate back to the infection site, where they help control the infection.  
 
1.3 Interaction between Mtb and mDCs 
Mtb express a range of different PAMPs that are recognized by PRRs on mDCs (Fig. 
1.4). Mtb is encapsulated by a layer of peptidoglycan (PGN), which is recognized by 
NOD1 and NOD2 in mDCs. Inside this PGN-cell wall, lipids with varying degrees of 
glycosylations are embedded. Of interest to mDC recognition is mannosylated 
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lipoarabinomannan (ManLAM) and phosphatidylinositol mannosides (PIMs), which 
can be mannosylated at different degrees. The CLR DC-SIGN (dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin) has a high affinity for 
$(1%2)-linked mannosyl residues, which are present on ManLAM and polar PIMs 
(like PIM6), but not apolar PIMs (like PIM1, 2 and 4).22,43 The mannose receptor 
(MR) has also shown to bind ManLAM and PIM6.43,44 PGN furthermore has lipopro-
teins such as LpqH, LprG, LprA, and PhoS1 embedded, which are recognized by 
TLR2.45 In its core, Mtb contains genomic DNA (gDNA), which has been suggested 
to trigger cytosolic PRRs such as AIM2 (absent in melanoma 2) and STING (stimula-
tor of interferon genes).46 gDNA also binds TLR9,47 but because of divergent reports 
on whether or not TLR9 is expressed in mDCs48–50 it is difficult to say whether TLR9 
is involved in Mtb-recognition in mDCs. TLR4 has also been attributed to protection 
against Mtb,51,52 and has been shown to be triggered by monoacylated muramyl di-
peptide (a constituent of PGN)53 and the newly discovered Mtb-ligand heparin-
binding hemagglutinin.54   
 
Upon activation of mDCs by Mtb, they undergo a process of maturation. They up-
regulate the antigen-presenting molecule major histocompatibility complex (MHC) 
class II, and the co-stimulatory molecules cluster of differentiation (CD)40, CD80 and 
CD86,28,55–57 and also the inhibitory ligand programmed cell death 1 ligand 1 (PD-
L1).58 They secrete interleukin (IL)-6, IL-10, TNF-$, IL-1$, IL-1#, IL-23 and IL-
12p70, but the latter is always in very small amounts.28,55–57 Collectively, the cyto-
kines secreted by mDCs upon interaction with Mtb are able to induce both T helper 
(Th)1 and Th17 responses, with the Th1 response being the most warranted for clear-
ance of the infection.  
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Fig. 1.4: Early interaction of Mtb with the immune system. Upon entrance of Mtb into the lungs, 
interaction between macrophages and myeloid dendritic cells (mDCs) occur. Mtb expresses a range of 
PAMPs and the immune cells expresses a range of PRRs. PAMPs and PRRs are indicated on the upper 
part of the figure. Mtb is not degraded in macrophages, and instead these cells become a reservoir for 
Mtb. mDCs on the other hand matures upon Mtb-interaction, visualized by the upregulation of surface 
markers, expression of cytokines and their migration to the draining lymph node. AIM2, absent in 
melanoma 2; CCR, C-C chemokine receptor; CD, cluster of differentiation; DC-SIGN, dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin; ManLAM, mannosylated lipoarabi-
nomannan; MR, mannose receptor; PGN, peptidoglycan; PD-L1, programmed cell death 1 ligand 1; 
PIM, phosphatidylinositol mannoside; STING, stimulator of interferon genes.  
 
1.4 Mtb and Th responses 
The role of a Th1 response during an Mtb infection is 1) to enhance the intracellular 
antimicrobial defenses of macrophages,59–62 and 2) to provide activation help for 
CD8+ cytotoxic T lymphocytes (CTLs) in order to kill infected macrophages.63–67 
Th1 cells activate macrophages by virtue of IFN-!, CD40ligand (CD40L)/CD40-
interactions, and T cell receptor (TCR)/MHC class II-interactions. This enables the 
Myeloid DC
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phagosome to fuse with the lysosome, and induces the production of reactive nitrogen 
and oxygen species inside the macrophage. Th1 cells provide help for CTLs by pro-
ducing IL-2, and increasing co-stimulatory molecule expression on the macrophage, 
mediating increased MHC class I co-stimulation for the CTLs. This enables perfor-
in/granzyme B-mediated killing of the infected macrophage. The importance of the 
Th1-response in keeping mycobacterial infections under control can be seen from 
patients with a mutation in one of the genes: IFNGR1, IFNGR2, STAT1, IL12B, and 
IL12BR1. Collectively these patients are diagnosed with a disease called “Mendelian 
susceptibility to mycobacterial disease”, and as the name of the disease reflects, these 
patients are highly susceptible to Mtb infection.68 Furthermore, IFN-! knockout mice 
quickly succumb to Mtb infection.69,70 
 
IL-12p70 is the most important mDC-produced cytokine for induction of a Th1 re-
sponse.71,72 However, IL-27 has also been linked with development of a Th1 response, 
e.g. by inducing naïve CD4+ T cells to upregulate IL-12R#2, and to express the Th1-
specific transcription factor T-box transcription factor TBX21 (T-bet).73,74 Another 
important Mtb-induced mDC-derived cytokine is IL-10. IL-10 has a general immune 
suppressive activity and can therefore both inhibit clearance of Mtb, and limit exacer-
bated pathologic immune activation. In experimental systems the former is often seen. 
For instance it has been shown that autocrine IL-10 suppresses mDC-mediated IL-
12p70 production and migration of mDCs to the lymph nodes during a mycobacterial 
infection.75 IL-10 knockout mice are also superior in withstanding Mtb-infection 
caused by a faster and enhanced Th1 response in the lungs.76 Furthermore, IL-10 has 
also been shown to inhibit autophagy, that otherwise would participate in the protec-
tive immune response against Mtb.77 
 
Mtb has also been shown to induce Th17-responses. For instance it has been shown 
that IL-17-producing long-lived central memory CD4+ T cells are found in the pe-
ripheral blood of mycobacteria-infected, otherwise healthy, human adults.78 Whether 
these peripheral blood Th17 cells has any protective role in the human immune re-
sponse to Mtb remains to be elucidated. In the murine system, it has been shown that 
Th17 cells impacts the Mtb-induced inflammation, but does not affect overall protec-
tive immunity.79,80 Another study has shown that an Mtb-induced Th17-response may 
be important in accelerating a Th1-recall response by inducing production of the 
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chemokines chemokine (C-X-C motif) ligand (CXCL)9, CXCL10 and CXCL11 by 
lung mucosal epithelial cells, which in turn recruits Mtb Ag-specific chemokine (C-
X-C motif) receptor (CXCR)3+ Th1 cells.81 Overall this suggests that Th17 responses 
are not necessarily needed for primary protection against Mtb, but may be useful in 
recall responses to boost Th1 responses. The Th17 response to Mtb is initiated in the 
lung draining lymph node when mDCs interact with naïve CD4+ T cells and prime 
them to become Th17 cells. Cytokines secreted by these mDCs are pivotal for the 
type of Th cell induced. IL-23, IL-1#, and IL-6 have been associated with the genera-
tion of effector human Th17 cells, although the exact combination of cytokines varies 
between studies.82–85 When using human thymic and umbilical cord blood naïve 
CD4+ T cells, the combination of IL-1# and IL-23 was especially important for Th17 
induction.86 Transforming growth factor (TGF)-# was for a while believed to inhibit 
Th17 induction,83–85 but recently it was demonstrated that TGF-# plays an indirect 
role in development of human Th17 cells, because Th17 cells are less susceptible to 
suppression by TGF-# than Th1 and Th2 cells are.87 Therefore TGF-# may play an 
indirect role in formation of Th17 cells by inhibiting differentiation into Th1 and Th2.  
 
Regulatory T cells (Tregs) are also induced during an Mtb-infection,88–90 and damp-
ens the immune response towards Mtb. For instance it was shown that depletion of 
Tregs in mice leads to a decreased number of Mtb in the lung and spleen,91 which 
may be caused by a Treg-mediated inhibition of effector T cell accumulation and 
function in the lungs, causing prolonged initial bacterial expansion.92 As one of the 
major effector molecules from Tregs is IL-10, mDC-derived IL-10 could also induce 
a delayed immune response against Mtb. Furthermore mDC-produced TGF-# and 
retinoic acid (RA) can also induce the generation of Tregs.93–96  
 
Fig. 1.5 summarizes the different Th responses seen during an Mtb infection, as well 
as their effector functions. The mDC-produced cytokines that leads to the induction of 
the different phenotypes are also shown on the figure.   
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Fig. 1.5: Summary of mDC-induced T helper responses against Mtb. An Mtb infection has been 
associated with T helper (Th)1, Th17 and regulatory T cell (Treg) responses. In order for naïve CD4+ 
T cells to differentiate into these specific subsets, instructions must be received from antigen-
presenting mDCs in the lymph nodes. Dependent on the PAMPs recognized by the mDCs different 
responses are initiated, demonstrated by different cytokine response patterns. The different DC-
produced cytokines linked with the differentiation into the T cell subsets are indicated on the figure. 
The shown cytokines have not all been confirmed to be induced in mDCs after Mtb interaction, but 
their role in Th differentiation has been determined elsewhere. The effector mechanism of the different 
Th cell subsets is described in the bottom of the figure. Phenotypic markers for Th cell subsets dis-
played on this figure: CD23R is the IL-23 receptor, CD212 is the IL-12p70 receptor (#1-subunit), 
CD25 is the IL-2 receptor ($-chain), and CTLA-4 (cytotoxic T-lymphocyte antigen-4) is a co-
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inhibitory receptor. Transcription factors specific for each Th cell subset are shown inside each Th 
subset. CTL, cytotoxic T-lymphocyte; FoxP3, forkhead box P3; HLA-DR, human leukocyte antigen-
DR; RA, retinoic acid; ROR!T, RAR-related orphan receptor !T; T-bet, T-box transcription factor 
TBX21; TCR, T cell receptor; TGF, transforming growth factor. 
 
1.5 Regulation of Th-inducing cytokines in mDCs 
Currently the conjecture is that Mtb induces both Th1 and Th17 responses, often in 
literature described as a Th1/Th17 response. However, reports have indicated that IL-
12p70 and IL-23 may be reciprocally regulated.27,28 Given the essentiality of IL-
12p70 and IL-23 in inducing human Th1 and Th17 cells respectively, the regulation 
of these cytokines within mDCs may play a central role for the initial immune re-
sponse against Mtb. Of the PRRs found in mDCs capable of recognizing Mtb, it has 
been shown that TLR4 and TLR9 signals through p38 and c-Jun N-terminal kinase 
(JNK)1/2 to induce IL-12p70 (Fig. 1.6).97–99 TLR2 and DC-SIGN have been shown to 
signal through extracellular-signal-regulated kinase (ERK)1/2 to induce IL-23, IL-1# 
and IL-10.23,100,101 DC-SIGN signaling furthermore include signaling through Raf-
1.101 ERK1/2 signaling and the transcription factor c-Fos has furthermore been shown 
to inhibit IL-12p70 production,97,99,102,103 although it is currently not known whether 
the inhibition is an indirect effect of an enhanced IL-10 production. Finally, triggering 
of MR induces signaling through IL-1 receptor-associated kinase 3 (IRAK-M),104 
which blocks TLR signaling.105 A summary of these signaling pathways induced by 
Mtb can be seen on Fig. 1.6. 
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Fig. 1.6: Intracellular signaling pathways regulating cytokine production in human myeloid den-
dritic cells. The optimal immune response Mtb would include a Th1 response, and signaling that in-
duces this type of response can be visualized by the prototypic IL-12p70-inducing stimuli LPS. Only 
little IL-12p70 production has been noticed after interaction between mDCs and Mtb, but whether this 
is due to a lack of triggering of the receptors inducing this response or an active inhibition of the re-
sponse is not known. It has been demonstrated that Mtb triggers the extracellular-signal-regulated ki-
nase (ERK) pathway, which has been linked with production of IL-1#, IL-23 and IL-10 and inhibition 
of IL-12p70 production, thus suggesting that active inhibition could take place. Green: Th1, blue: Th17, 
red: immune dampening. IRAK-M, IL-1 receptor-associated kinase 3; JNK, c-Jun N-terminal kinase; 
MEK, mitogen activated protein kinase/ERK kinase; PI3K, Phosphatidylinositol 3’ kinase. 
 
Of major importance to the development of the immune response against Mtb, is a 
very low, almost neglectable, production of IL-12p70 by human mDCs.28,55–57 Two 
different schemas could explain the diminished Mtb-induced IL-12p70 response in 
mDCs: 1) There is too little/no triggering of IL-12p70-promoting TLRs in mDCs after 
interaction with Mtb, and/or 2) Mtb triggers pathways that actively downregulate IL-
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12p70 induction. Experiments have shown that blocking the ERK or phosphatidylino-
sitol 3-kinase (PI3K) pathways in monocyte-derived macrophages increases IL-12p70 
production after Mtb-triggering,106 thus suggesting that the latter scenario could be in 
play. Further evidence for mechanisms that actively repress IL-12p70 production has 
recently been published.27 It was shown that the TLR2/CLR ligand zymosan activates 
transcriptional repressors (hairy and enchancer of split-1 (Hes)1, Hes5, 
hairy/enhancer-of-split related with YRPW motif protein (Hey)1 and transducin-like 
enhancer of split (TLE)) of IL12A (encoding IL-12p35 subunit of IL-12p70) leading 
to c-Rel dissociation from the IL12A promoter. LPS on the other hand did not induce 
these repressors, enabling c-Rel to stay on the il12a promoter region for a longer peri-
od of time, leading to transcription of IL-12p35, and production of bioactive IL-12p70 
protein.  
 
1.6 Monocyte-derived DCs as an experimental system 
Much of what we know about the interaction between Mtb and mDCs originate from 
research conducted on an in vitro analogue to the mDCs found in vivo. These in vitro 
generated mDCs are called monocyte-derived DCs (moDCs), because they are differ-
entiated from monocytes in culture using a combination of IL-4 and granulocyte-
macrophage colony-stimulating factor (GM-CSF).107 Blood-derived mDCs and 
moDCs share many of the same properties such as TLR-expression-repertoire and the 
cytokines secreted in response to TLR-ligation.108 The main advantage of using 
moDCs is the ability to generate large amounts of cells to study (typically 3-
6*107/donor after differentiation). Blood-derived mDCs are very scarce, typically 
constituting 0.3-0.9% of peripheral blood mononuclear cells (PBMCs),109,110 and giv-
ing a yield of 2-5*105/donor after purification. Lung-resident mDCs are even harder 
to study, as acquisition of these requires an invasive biopsy, and can only be acquired 
from surgeries of therapeutic or diagnostic purposes such as thoracotomies, lobecto-
mia or pneumectomia.111,112 Ten Berge et al.113 furthermore argues against the use of 
such tissue, as the diseased tissue, and the subsequent enzymatic tissue-digestion step 
may have influenced the phenotype and function of the mDCs. Instead Ten Berge et 
al. suggest using mDCs from bronchoalveolar lavage fluid (BALF). However, like the 
blood-derived mDCs, the numbers of mDCs in BALF are very scarce, and typically 
only 5-10*104 mDCs/donor can be acquired prior to any purification steps.114 By vir-
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tue of the large amount of moDCs that can be generated, advanced studies such as 
kinome-wide phosphoproteomics can be conducted. It has furthermore been demon-
strated that moDCs migrate into the lungs of mice,115 suggesting a direct in vivo rele-
vance of moDCs in Mtb-infection. Confirming the results obtained from moDC stud-
ies in lung-resident mDCs is desirable, but outside the scope of this thesis. 
 
1.7 Motivation for paper 1-3 
The motivation behind three of the papers included in this thesis has been to deter-
mine how Mtb evades propagation of protective immunity by subverting the pheno-
type of human moDCs. Paper 1 focuses on the plasticity of moDCs, and demonstrates 
a donor-dependent ability of monocytes to differentiate into two distinct moDC sub-
types, with only one of them being capable of producing Th1-propagating IL-12p70. 
Paper 1 furthermore demonstrates how Mtb exploits plasticity in the IL-12p70-
competent moDCs to induce a subset of cells that lacks IL-12p70-competence. In pa-
per 2, a method for isolation of the IL-12p70-competent moDCs is described, and 
paper 3 focuses on the use of these purified IL-12p70-competent moDCs to study the 
signaling-transduction networks induced by Mtb in moDCs. The phenotype of naïve 
CD4+CD45RA+ T cells co-cultured with Mtb-primed moDCs was also examined, 
and in paper 3 it is demonstrated how Mtb skews the Th response towards Th17. The 
outcome of these studies can be found in chapters 2, 3 and 4. 
 
1.8 The host immune response against HIV-1  
HIV-1 does not kill a person by means of cytotoxic attacks like other lethal microor-
ganisms. Instead it eliminates the patient’s Th cell-based immune system, leaving the 
body unprotected from other infections. This eradication of the immune system leads 
to the disease called AIDS. In recent years much focus has been given to the early 
events after HIV-1 enters the body, and the initial period before peak viraemia 21-28 
days after infection has been called the window of opportunity for eradication of the 
infection.15,116 Therefore understanding the initial interaction between HIV-1 and the 
immune system could lead to new treatment strategies for this deadly infection.   
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HIV-1 enters the body at vaginal and rectal mucosal surfaces.15 Here they interact 
with cells from the immune system expressing the surface molecule CD4. This in-
cludes T cells, macrophages and different DCs (Fig. 1.7 and 1.8). The HIV-1 enve-
lope glycoprotein (gp)120 binds CD4 on human immune cells in combination with 
one of the two co-receptors C-C chemokine receptor (CCR)5 and C-X-C chemokine 
receptor (CXCR)4.117–119 Initially gp120 binds CD4, which induces conformational 
changes in gp120 that enables binding to a co-receptor.120 This triggers a second con-
formational change that allows insertion of a fusion peptide into the host cell mem-
brane.121,122 This, in turn, enables HIV-1 to enter the host cell and integrate into the 
host genome, thereby resulting in viral replication (Fig. 1.7).  
 
Fig. 1.7: Schematic representation of the HIV-1 life cycle. HIV-1 enters immune cells upon interac-
tion with CD4 and one of the chemokine receptors CCR5 and chemokine (C-X-C motif) receptor 
(CXCR)4. Inside the cell HIV’s RNA genome is reverse transcribed into DNA, which subsequently is 
integrated into the host genome. Consequently, HIV-1 can use the host cell’s own machinery to repli-
cate, when the cell needs to transcribe the genes that HIV-1 has integrated into. NF-"B is among the 
transcription factors shown to induce viral replication. The de novo generated viral RNA encodes pro-
teins needed for the viral capsid and assembly thereof. When new viral particles have assembled, HIV-
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1 buds from the host cell and is subsequently capable of infecting new cells. Env, gp120; LTR, long 
terminal repeat.123 
 
On the basis of the two types of co-receptors, different HIV-1 strains have been divid-
ed into two tropisms, namely CCR5 tropic (R5) and CXCR4 tropic (X4) HIV-1 
strains. Individuals infected with HIV-1 are exposed to many different HIV-1 strains 
at the mucosal surface, but only few HIV-1 strains are able to establish 
infection.116,124,125 Recent data has indicated that in 70-80% of cases the founder 
population originates from a single virion.116 In far the most cases, this strain is R5 
and not X4,124,125 but currently the reason for this tropism-selectivity is not fully un-
derstood. The major targets for X4 HIV-1 strains are naïve CD4+ T cells and thymic 
precursors,126,127 while the major targets for R5 HIV-1 strains are effector T cells and 
macrophages.127–129 Infection of effector memory T cells present at the mucosal sur-
faces, leads to viral replication and apoptosis of the T cells (Fig. 1.8).130–132 Macro-
phages on the other hand are more resistant to the cytopathic effect of HIV-1,133,134 
and therefore acts as a long-term reservoir for HIV-1 (Fig. 1.8).129 Macrophages have 
furthermore been shown to be involved in transferring HIV-1 to T cells,135,136 but 
whether they play any protective role during an HIV-1 infection is not known.  
 
1.9 DCs and HIV-1 
Different types of DCs are also present at the mucosal surfaces. In humans it has been 
shown that CD11c+DC-SIGN+MHC class II+ mDCs are present in the lamina pro-
pria and the interfollicular regions of Peyer’s patches, and IL-3R+MHC class II+ 
plasmacytoid DCs (pDCs) are present in the high endothelial venules and the interfol-
licular regions of Peyer’s patches.137 Furthermore pDCs arrive at the site of simian 
immunodeficiency virus (SIV)-infection in rhesus macaques as early as one day after 
infection,138 indicating that they could play an important role in the early phase of the 
immune response against HIV-1. Both mDCs and pDCs express CCR5 and CXCR4 
and are therefore capable of interacting with HIV-1 strains from both tropisms (Fig. 
1.8). As described earlier, DCs play a major part in initiating the adaptive immune 
response and are therefore very important in the anti-viral immune response. Usually 
when DCs encounter an intruding pathogen they advance from an immature state to 
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an activated state characterized by the upregulation and secretion of several different 
immune regulatory proteins. Notably, mDCs are not activated by HIV-1 even though 
they express TLR8 capable of recognizing ssRNA (Fig. 1.8).139,140 pDCs on the other 
hand do get activated by HIV-1, and upon interaction, pDCs produce type I IFNs, up-
regulate antigen-presenting, co-stimulatory and inhibitory molecules, and gain migra-
tory capacity towards chemokine (C-C motif) ligand (CCL)19 by upregulation of 
CCR7140–143 (Fig. 1.8). 
 
 
Fig. 1.8: Proposed initial interactions between HIV-1 and the immune system. HIV-1 enters the 
body at mucosal surfaces where interaction between the virus and immune cells expressing CD4 and 
CCR5 is taking place. The upper panel shows receptors on the immune cells capable of interacting with 
HIV-1. The lower panel shows the effect of interaction with HIV-1 on the immune cell phenotype. 
Upon interaction with HIV-1, memory T cells and macrophages are infected and either undergo apop-
tosis or act as a reservoir for HIV-1 replication. mDCs are not infected or activated by HIV-1. 
Plasmacytoid DCs (pDCs) are activated leading to secretion of type I IFNs and upregulation of a range 
of surface markers. BDCA, blood dendritic cell antigen; DCIR, dendritic cell immunoreceptor; IDO, 
indoleamine 2,3-dioxygenase; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.  
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1.10 Recognition of HIV-1 by pDCs 
pDCs express a number of receptors capable of recognizing various PAMPs from 
HIV-1.144 In the endosomes, TLR7 and TLR9 are localized and recognize single-
stranded (ss)RNA and double-stranded (ds)DNA/unmethylated CpG sequences, re-
spectively. In the cytosolic compartment RIG-I recognizes 5’ triphosphorylated 
ssRNAs and relatively short dsRNA, and melanoma-differentiation-associated gene 5 
(MDA5) recognizes long dsRNAs. Curiously, DNA retrotranscripts do not activate 
pDCs.141 One reason for the inactivity of HIV-1 DNA is the low frequency of CpG 
motifs when compared to bacterial and other viral DNAs.145 Recently HIV-1 has been 
shown to be recognized by RIG-I in PBMCs and monocyte-derived macrophages,146 
but these findings have not yet been replicated in pDCs. It is therefore currently be-
lieved that the main PRR in pDCs for HIV-1 recognition is TLR7.141 Besides ssRNA, 
HIV-1 also carries a CLR-triggering ligand, namely high-mannose structures present 
on gp120. These high-mannose structures have been shown to interact with a range of 
receptors both on pDCs and mDCs. On pDCs, blood dendritic cell antigen (BDCA)-
221 and dendritic cell immunoreceptor (DCIR)19,147 are able to bind gp120. mDCs also 
express DCIR, and furthermore express MR and DC-SIGN. Gp120-ligation to CLRs 
has been shown to modulate TLR-triggered signaling in both DC subtypes,147–149 and 
it has been suggested that the lack of HIV-1-mediated activation of mDCs could be 
promoted by high-mannose-CLR-signaling.  
 
1.11 Effector mechanisms of pDC activation 
Probably the most important effect of pDC activation by HIV-1 is a very rapid pro-
duction of type I IFNs. pDCs are especially fast at inducing IFN-! compared to other 
immune cells, as pDCs constitutively express IRF7 necessary for IFN-! induction.150 
IFN-! has a direct killing effect on HIV-1, but also plays a role in the activation of 
other immune cells (Fig. 1.9). It has been shown that mDCs can be activated during 
an HIV-1 infection by virtue of pDC-derived type I IFNs.140 pDC-derived type I IFN 
also activates natural killer (NK) cells,151 and has in general been shown to induce 
Th1 polarization as evidenced by T-bet expression.152 pDC-derived IFN-! further-
more limits HIV-1 replication in CD4+ T cells,153,154 but prolonged IFN-! production 
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can also lead to T cell death by TNF-related apoptosis-inducing ligand (TRAIL)-
mediated apoptosis.155,156 Hence, type I IFNs can both have beneficial and detrimental 
effects on the immune response against HIV-1. Another detrimental effect of HIV-
activation of pDCs is the upregulation of indoleamine 2,3-dioxygenase (IDO), which 
in turn induces naïve CD4+ T cells to differentiate into Tregs.157,158 These Tregs sup-
press T cell proliferation and mDC maturation. As for the dichotomy seen for IFN-$, 
it is currently not known whether IDO-expression has a beneficial effect by decreas-
ing the immunopathology or a detrimental effect by inhibiting proper viral clearance.  
 
 
Fig. 1.9: Effect of HIV-1-mediated pDC-activation on other immune cells. The main effector mole-
cules induced after activation of pDCs by HIV-1 is type I IFNs. These have both beneficial (green 
lines) and detrimental (red lines) effect on the immune response towards HIV-1. pDCs also upregulate 
IDO, which has an immune dampening effect. CD56 is a NK cell specific marker. TNF, tumor necrosis 
factor. 
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1.12 Motivation for paper 4 
Studies on CLR-TLR crosstalk in pDCs has been conducted using recombinant 
gp120, or Ab-triggering of receptors. Recently it was demonstrated how glycosylation 
patterns on recombinant gp120 is affected by the expression system used to produce 
the protein, and may therefore not reflect natural HIV-1 glycosylation.159 Consequent-
ly, it is currently not known if HIV-1 natural gp120 glycosylation will affect the phe-
notype of pDCs. Given the very important role pDCs plays in the anti-viral immune 
response, gp120-mediated dampening of pDC activity could have dire consequences 
for the immune response against HIV-1. Therefore, paper 4 focused on the interaction 
between pDCs and HIV-1, and elucidation of the role played by high-mannose struc-
tures for immune evasion (Fig. 1.10). This paper can be found in chapter 5. 
 
Fig. 1.10: Potential cross-regulation between TLR7 and CLRs in pDCs. pDCs mainly recognize 
HIV-1 by virtue of TLR7, but CLRs have also been shown to bind HIV-1 glycoprotein (gp)120. The 
cross-regulation between these receptors has not been thoroughly investigated and has therefore been 
the focus of paper 4 in this thesis. TRAF, TNF receptor associated factor. 
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2.1 Abstract 
Immunity against Mycobacterium tuberculosis (Mtb) depends on the way dendritic 
cells (DCs) interpret the bacterial constituent matters. Given the intracellular character 
of Mtb, a preferable DC signature is based particularly on IL-12p70 to propagate IFN-
!-producing CD4+ T-cells. Therefore it is perplexing that IL-12p70 levels are weak in 
monocyte-derived DCs (moDCs) in response to Mtb. Here we report that Mtb modi-
fies moDC plasticity by expanding a CD14-high expressing subset with weak IL-
12p70-producing capacity. CD1a expression levels were found to divide moDCs into 
two subsets at the immature state, while enhanced CD14 defined a third subset propa-
gated after Mtb activation, but not by lipopolysaccharide (LPS). Irrespective of LPS- 
or Mtb-stimulation, the CD1a-high, CD14-low moDCs proved the main IL-12 family 
cytokine producers. The Mtb-promoted subset, characterized by CD14-high expres-
sion, exhibited similar chemokine receptor and cytokine expression patterns as CD1a-
low moDCs; being weak IL-12p70 producers and poor expanders of IFN-! in naïve 
CD4+ T-cells. Mtb-derived peptidoglycan and mannosylated lipoarabinomannan part-
ly explained the subset propagation. Addition of IFN-!, but neither IL-17A nor IL-22, 
inhibited the characteristic subset division and promoted high level IL-12p70 in Mtb-
challenged moDCs. We conclude that Mtb exploit moDC plasticity to reduce produc-
tion of IL-12p70, being entirely divertible by exogenous IFN-!. 
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2.2 Introduction  
A Mycobacterium tuberculosis (Mtb) infection originates by inhalation of the bacteria 
into the lungs. The first tissue-resident cells Mtb interacts with are therefore the al-
veolar macrophages and dendritic cells (DCs).35–37 Mtb avoid getting killed by phago-
cytosing macrophages by inhibiting fusion of the Mtb-containing phagosome with the 
lysosome, and by inhibiting autophagy.40,77 Consequently, Mtb obtains status as an 
intracellular microbe that survives within lung-resident macrophages. Clearance of 
this type of pathogen most essentially requires a CD4+ Th1 immune response needed 
to activate infected macrophages and to provide help for CD8+ cytotoxic T lympho-
cytes capable of killing infected cells.59–61,66 Because DCs are the only cells capable 
of activating naïve T cells, the way DCs respond to Mtb becomes a critical factor for 
how the immune response to Mtb evolves. DC-produced IL-12p70 is imperative for 
induction of a Th1 response,71,72 and is enhanced by IL-27.73,74 IL-1#, IL-6, and IL-23 
are important for development of human Th17 cells,82–85 that per se function to recruit 
neutrophils, but the role of Th17 cells during an Mtb-infection in humans has not yet 
been elucidated.160 IL-10 acts as a general immunosuppressive cytokine, and plays a 
specific part during an Mtb-infection by inhibiting autophagy.77,161 The remarkable 
functional plasticity of DCs to induce these different types of responses depends on 
which signals the DCs receive from the environment.162 For example, single-
triggering of toll-like receptor (TLR)2 and nucleotide oligomerization domain (NOD) 
2 in moDCs gives rise to very low level IL-12p70, while the combined triggering 
gives intermediate amounts of IL-12p70.28 Single-triggering of TLR4 on the other 
hand, gives higher amounts of IL-12p70,97 while triggering of C-type lectin receptors 
(CLRs) dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN, CD209) and the mannose receptor (MR, CD206) inhibits TLR4-
mediated IL-12p70 production, perhaps via increased IL-10 production.22,26 It is well-
established that Mtb contains ligands for both TLR2 and NOD2, by virtue of lipopro-
teins and muramyldipeptid (MDP), but it has also been suggested that Mtb contains 
non-canonical ligands for TLR4.53,54,163 Furthermore, Mtb contains genomic DNA 
that can signal through intracellular DNA sensors TLR9 and stimulator of interferon 
genes (STING) to induce type I IFNs50,164 that has been shown to boost IL-12p70 
production in an autocrine manner.165 It is therefore curious that Mtb only induces 
very small, almost undetectable amounts of IL-12p70 in moDCs.28,55–57 Inhibitory 
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signaling by the Mtb-expressed CLR-ligands mannosylated lipoarabinomannan 
(ManLAM) and phosphatidylinositol mannoside 6 (PIM6) may partly explain the low 
IL-12p70,22,26,166,167 but other factors, for instance relating to the host responsiveness 
are likely to play a part. 
 
Studies on functional plasticity of moDCs have generally focused on cytokine-
profiles and little is known about surface markers that can distinguish moDCs with 
different properties. Since the discovery of moDCs they have been described as being 
CD1a+ and CD14-low/negative.107 However, interference during differentiation by 
IL-10, TLR ligands, and Mtb has been shown to generate DCs that do not express 
CD1a.168–171 These CD1a-negative DCs were shown to be poor IL-12p70 producers, 
hence suggesting a linkage between CD1a-expression and IL-12p70 production.  
In this report we analyzed how the expression-level of CD1a and other surface mark-
ers on moDC preparations affects the response to Mtb. We report that three different 
moDC subsets can be identified after Mtb-stimulation, one of them being specifically 
induced by Mtb. 
 
2.3 Materials and Methods 
Reagents. The following reagent was obtained through the NIH Biodefense and 
Emerging Infections Research Resources Repository, NIAID, NIH: Mycobacterium 
tuberculosis, strain H37Rv, !-irradiated whole cells, NR-14819, Mtb, strain H37Rv 
purified peptidoglycan (PGN), NR-14853, and purified ManLAM from strain Mtb 
H37Rv, NR-14848. E. coli LPS (O26:B6) was purchased from Sigma Aldrich. Re-
combinant human IFN-! (cat. # 285-IF), IL-17A (317-ILB), and IL-22 (782-IL) was 
purchased from R & D Systems. The following anti-human Abs were used in the 
studies: CD1a/PE (clone# HI149), HLA-DR/v500 (G46-6), CD86/v450 (2331(FUN-
1)), PD-L1/PE-Cy7 (M1H1), DC-SIGN/FITC (DCN46), MR/APC (19.2), 
CCR2/AF647 (48607), CCR5/APC-Cy7 (2D7/CCR5)  (all from BD Biosciences), 
CCR7/APC-eFlour780 (3D12), CD14/PE-Cy7 (61D3), CD45RA/APC (HI100) (all 
from eBioscience), CD16/FITC (3G8), CD40/PerCP-Cy5.5 (5C3) (both from Bio-
legend), and CD4/ECD (SFCI12T4D11) (Beckman Coulter). 
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Human blood samples. Human buffy coats were acquired from the blood bank at the 
National Hospital of Denmark (Rigshospitalet) collected from anonymous healthy 
donors. Blood samples were handled in accordance with guidelines put forward in the 
“Transfusion Medicine Standards” by the Danish Society for Clinical Immunology 
(www.dski.dk). The buffy coats were obtained from 450 mL whole blood donations 
in citrate phosphate dextrose anticoagulant. Whole blood was fractionated to separate 
the majority of erythrocytes and plasma. The buffy coat contains approximately 90% 
of the leukocytes from the 450 mL of blood, and was used within 5.5 hours upon 
blood draw. 
 
Cell purification and culture. Peripheral blood mononuclear cells (PBMCs) were 
isolated from human buffy coats by Ficoll-Paque (GE Healthcare) density centrifuga-
tion. The PBMCs were labeled with magnetic-particle linked CD14 Abs and isolated 
using MACS (Miltenyi). Cells were cultured in RPMI 1640 (Lonza) containing 2% 
(volume to volume) L-glutamine (Lonza), 10% fetal bovine serum (FBS, Lonza), 1% 
penicillin, streptomycin (Lonza), 50 &M #-mercaptoethanol (Sigma-Aldrich) and 10 
mM HEPES (Lonza). Cells were kept in a humidified 37°C, 5% CO2 incubator. For 
differentiation of monocytes into immature DCs, the medium was supplied with 20 
ng/mL ('160 U/mL) recombinant human GM-CSF and 30 ng/mL ('150 U/mL) re-
combinant human IL-4 (both CellGenix). The cells were grown in polystyrene 6 well 
plates (Nunc) at a concentration of 2*106/mL. Monocyte cultures were supplied with 
fresh medium containing fresh GM-CSF and IL-4 on day 3, and non-adherent imma-
ture DCs were harvested on day 6. In some experiments CD1a-hi moDCs were en-
riched by MACS according to the manufacturer’s instructions. The purity of CD1a-hi 
moDCs were >92% for all donors. Immature DCs were plated at a cell concentration 
of 106/mL and stimulated with 500 ng/mL LPS, 10 &g/mL PGN, 50 &g/mL ManLAM 
and 500 &g/mL Mtb (final concentrations) determined as optimal concentrations in 
dose-response experiments (data not shown). Right before adding Mtb, clumps of 
bacteria was disrupted through syringe shearing by passing the solution 10 times 
through continuously smaller needles in the order 18-, 21-, 23-, 25- and 27-gauge. 
Recombinant human IFN-!, IL-17A, and IL-22 was added at 100 ng/mL. 
 
ELISA. ELISA was performed according to the manufacturer’s instructions. Superna-
tants of stimulated and unstimulated DCs were harvested after 24 hours and kept at -
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40°C until analysis. The following ELISA kits were used in this study: human IL-1#, 
IL-6, IL-10, IL-12, IL-27, IFN-! (all R&D Systems), and IL-23p19p40 (eBioscience). 
 
Flow cytometry. Flow cytometry was performed according to standard procedures. 
The wash and staining buffer consisted of PBS with 1% FBS and 0.1% Na-azid (Sig-
ma-Aldrich). Before staining, the cells were incubated for 10 minutes in staining 
buffer with 2% allogeneic human AB plasma (Rigshospitalet) to limit non-specific 
binding of Abs. Monocytes were analyzed right after isolation, immature moDCs 
were analyzed right after harvesting, and stimulated/unstimulated moDCs were ana-
lyzed after 24 hours. 
 
CD4+ naïve T cell co-culture. PBMCs were enriched for CD3+ cells by Dynabeads 
FlowComp human CD3-kit (Invitrogen), which enables removal of magnetic labeled 
Abs before cell sorting. Subsequently CD3-enriched PBMCs were labeled with anti-
bodies against CD4/ECD and CD45RA/APC and sorted on MoFlo XDP (Beckman 
Coulter) according to CD4+CD45RA++. Purity of T cells were assayed on 
FACSCanto II, and were >97% for all donors. Prior to the co-culture moDCs were 
stimulated with the respective stimuli for 6 hours. moDCs were washed, counted, and 
added in a ratio of 1:20 to naïve T cells. T cells and moDCs were co-cultured for 6 
days.  
 
Statistics. All data was tested for a Gaussian distribution using a D’Agostino & Pear-
son omnibus test. Data that did not follow a Gaussian distribution were either log-
transformed or analyzed by a non-parametric statistical method. When comparing two 
samples, the student’s paired t-test or the Wilcoxon matched-pairs signed rank test 
was used. When comparing more than two samples a repeated measures ANOVA, or 
the Kruskal-Wallis test with a Dunn’s post-hoc test was used. All correlation analyses 
are based on Pearson or Spearman correlations. Prism 5 (Graphpad Software) was 
used to conduct the analyses.  
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2.4 Results 
CD1a-high and CD1a-low moDCs respond differently to Mtb 
To gain insight into the relationship between CD1a-expression and moDC response 
patterns towards Mtb, we generated moDCs from a range of donors and assayed if the 
level of CD1a differed between donors (Fig. 1A-C). Interestingly, we found that even 
though all moDCs expressed CD1a, a clear division of two moDC subsets based on 
CD1a could be made (Fig. 1A). One subset expressed CD1a on average at a 25-fold 
higher level than the other subset, while this subset expressed CD1a on average 53-
fold greater than monocytes originating from the same donor (Fig. 1B). The two 
moDC subsets were labeled CD1a-high (CD1a-hi) and CD1a-low (CD1a-lo). Nota-
bly, different donors gave rise to very different levels of CD1a-hi (versus CD1a-lo) 
moDCs. The number of CD1a-hi moDCs followed a Gaussian distribution with a 
mean percentage of CD1a-hi at 63% (range 25-96%, n = 23). It has previously been 
reported that moDCs lacking the expression of CD1a are low IL-12p70 producers.168–
171 In line with this we correlated the cytokines produced after Mtb stimulation with 
the percentage of CD1a-hi DCs (Fig. 1C). We analyzed a range of DC cytokines tra-
ditionally used in directing the naïve Th response towards Mtb: IL-12p70 and IL-27 
for Th1, IL-1#, IL-6, and IL-23 for Th17, and IL-10 as a general immunosuppressive 
cytokine. Correlation analysis showed that the strongest association between the per-
centages of CD1a-hi DCs and cytokine level was seen for the IL-12 family cytokines: 
IL-12p70, IL-23 and IL-27, where high level CD1a-hi increased the amount of cyto-
kine produced (Fig. 1C). IL-1# was produced in slightly larger amounts and IL-6 in 
slightly smaller amounts when more CD1a-hi DCs were present. There was a small 
tendency towards the CD1a-lo subset inducing the most IL-10, although this was not 
statistically significant.   
 
To further analyze the phenotype of the two CD1a-divided DC subsets, we measured 
a range of surface markers by flow cytometry, and gated on the CD1-hi and CD1a-lo 
to define their expression levels on the two populations. In line with what we found 
for cytokine expression levels, the CD1a-hi subset was found to express higher levels 
of immunogenic markers than the CD1a-lo subset upon Mtb challenge (Fig. 1D-F). 
The antigen-presenting and co-stimulatory molecules HLA-DR, CD86 and CD40 
were upregulated on average 1.3, 2.9 and 2.9 respectively by the CD1a-hi subset 
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compared to the CD1a-lo subset. The lymph-node homing receptor CCR7, and the 
CLR DC-SIGN displayed similar expression levels in the two subsets. MR, pro-
grammed cell death 1 ligand 1 (PD-L1, CD274), CD16, CCR2, and CCR5 were all 
upregulated the most in the CD1a-lo DC subset, at a 1.9, 1.6, 3.0, 2.1, and 2.3 higher 
level respectively compared to the CD1a-hi DC subset.  
 
To assay if the difference in phenotype between CD1a-lo and CD1a-hi moDCs could 
be conveyed in the level of IFN-!-producing CD4+ naïve T cells, we conducted a co-
culture experiment, using different levels of CD1a-hi moDCs from the same donors. 
After a 6-day co-culture, the IFN-! produced by the naïve CD4+ T cells were shown 
to positively correlate with the number of CD1a-hi moDCs (Fig. 1G).  
 
 
Figure 1: CD1a-dependent moDC response patterns against M. tuberculosis. Monocyte-derived 
DCs (moDCs) were stimulated with M. tuberculosis (Mtb) for 24 hours, and phenotypically analyzed 
by flow cytometry (A, B, D-F) or ELISA (C & F).  A) FSC properties versus expression of CD1a on 
Mtb-activated moDCs (representative for n = 23). B) Monocytes and moDCs from the same donors 
were analyzed by flow cytometry to access CD1a expression levels. C) Supernatants from Mtb-
!"
#"
$"
%"
&'()*+"
,*-."
,*/!"
0+"
*,)1234"
,,+5"
6*)'#"
,*#."
,,+$"
,,+7"
0
1000
2000
3000
4000
5000 ***
0
5000
10000
15000
20000
25000 ***
0
5000
10000
15000
20000 ***
0
2000
4000
6000
8000 ***
0
1000
2000
3000
4000 ***
0
1000
2000
3000 ns
0
200
400
600 *
0
500
1000
1500 ns
0
50
100
150
200 *
0
500
1000
1500 **
IL-1!
0 20 40 60 80 100
0
2
4
6
8 r = 0.44
p = 0.037
% CD1a-hi DCs
IL-12p70
0 20 40 60 80 100
0.0
0.1
0.2
0.3
0.4
0.5 r = 0.63
p = 0.0013
% CD1a-hi DCs
IL-6
0 20 40 60 80 100
0
20
40
60
80 r = -0.44
p = 0.04
% CD1a-hi DCs
IL-23
0 20 40 60 80 100
0
5
10
15 r = 0.80
p < 0.0001
% CD1a-hi DCs
IL-10
0 20 40 60 80 100
0
5
10
15
20
25 r = -0.23
p = 0.28
% CD1a-hi DCs
IL-27
0 20 40 60 80 100
0
2
4
6
8
10 r = 0.74
p = 0.0003
% CD1a-hi DCs
HLA-DR
PD-L1
CD40CD86 DC-SIGN
CD16CCR7
M
FI
M
FI
MR
CCR2 CCR5
! CD1a-lo        " CD1a-hi
Mo
no
cy
tes
CD
1a
-lo
CD
1a
-lo
 + 
Mt
b
CD
1a
-hi
CD
1a
-hi
 + 
Mt
b
1
10
100
1000
10000
100000
*
**
C
D
1a
 M
FI
0102 103 104 105
0
50K
100K
150K
200K
250K
CD1a
FS
C
A) B)
D)
0 102 103 104 105
0
20
40
60
80
100
0 102 103 104 105 0 102 103 104 105
0 102 103 104 105
0
20
40
60
80
100
0 102 103 104 105 0 103 104 105
0 102 103 104 105
0
20
40
60
80
100
0 102 103 104 105 0102 103 104 105 0 102 103 104 105
HLA-DR CD86 CD40
MR DC-SIGN CCR7
PD-L1 CD16 CCR5 CCR2
CD1a-lo
CD1a-hi
%
 o
f m
ax
%
 o
f m
ax
%
 o
f m
ax
E) F)
G)
0 
1 
2 
3 
0 50 100 
%CD1a-hi moDCs
T 
ce
ll 
IF
N
-#
 
(n
g/
m
L)
ng
/m
L
ng
/m
L
C)
- 29 - 
activated moDCs were assayed by ELISA and correlated with percentages of CD1a-hi DCs. Each dot 
represents one donor, and the line in the diagrams is the trend line shown for easier visual interpreta-
tion. D-E) Mtb-stimulated moDCs were gated into two populations determined by CD1a-expression. 
Ten other surface markers were assayed and mean fluorescence values (MFI) values extracted. Each 
dot in E) represents one donor, and the error bars represents SD. F) The ratio of CD1a-hi/CD1a-lo in 
expression level of the 10 surface markers was calculated for each donor, and the average of all donors 
(n = 4-11) plotted as shown. The numbers on the y-axis denominates the CD1a-hi/CD1a-lo MFI ratio, 
and the dotted line represents equal expression level on the two DC subsets. G) Different proportions 
of Mtb-primed CD1a-hi moDCs from the same donor were co-cultured with naïve CD4+ T cells for 6 
days, and supernatant assayed for IFN-" production. The data is representative for 2 independent ex-
periments, and error bars represent SD of duplicates. Data in B) was tested for statistical significance 
by the Kruskal-Wallis test and Dunn’s post-hoc test (n = 11). Data in E) were tested by a student’s two-
tailed paired t-test, or a Wilcoxon matched-pairs signed rank test (n = 4-11). Correlation analysis (in C) 
was done by a Pearson or a Spearman correlation test (n = 20-23). *p<0.05, **p<0.01, ***p<0.001. 
 
 
CD1a-hi moDCs are relatively poor IL-12p70 inducers in response to Mtb 
In the assayed range of donors it was apparent that a high amount of CD1a-hi moDCs 
were needed to produce any IL-12p70 at all in response to Mtb. To further elaborate 
on this, we compared the Mtb-induced response pattern in moDCs to moDCs stimu-
lated with a prototypic IL-12p70-inducing ligand LPS (Fig. 2). When comparing with 
Mtb, especially IL-12p70, but also IL-27 was induced to the highest levels by LPS in 
CD1a-hi, and also in CD1a-lo moDCs (Fig. 2A, B). IL-1# and IL-23 were induced at 
the highest level by Mtb, while IL-6 and IL-10 was induced at a similar level by the 
two different stimuli. The pattern of cytokines was similar in CD1a-hi and CD1a-lo 
moDCs, but the levels varied, as already exemplified in Fig. 1C. To examine if these 
results could be explained by differences in surface marker display, we compared the 
expression level of a range of surface markers between Mtb- and LPS-stimulated 
moDCs gated on CD1a-hi and CD1a-lo moDCs (Fig. 2C,D). Most of the surface 
markers were expressed at similar levels, but notably LPS upregulated CD40 the 
most. Particularly, there was a large increase in CD40 on the LPS challenged CD1a-lo 
moDCs. However, the largest difference between LPS and Mtb activated moDCs was 
for CD14-expression. Both CD1a-hi and CD1a-lo Mtb-stimulated moDCs were found 
to upregulate CD14 to a higher level than in LPS (on average 21.5 and 13.6 fold in-
crease on CD1-hi and CD1a-lo, respectively). The level of CD14 expression in Mtb-
activated moDCs was also higher than the level found in unstimulated moDCs. Com-
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pared to unstimulated moDCs, Mtb-activated CD1a-hi and CD1a-lo moDCs had on 
average a 6.6 and 6.3 fold higher expression of CD14. 
 
Figure 2: Response pattern-comparison of CD1a-hi and CD1a-lo moDCs between LPS and Mtb. 
moDCs were stimulated with Mtb and LPS, or left unstimulated for 24 hours and analyzed for surface 
marker expression by flow cytometry, and secreted cytokines by ELISA. For cytokine comparisons (A, 
B), the percentage of CD1a-hi DCs were noted and used to separate the DCs and thereby the response 
patterns into two groups based on <50% CD1a-hi expressing DCs (n = 7) or >80% CD1a-hi expressing 
(n = 6). For surface marker comparison (C, D) all donors were used (n = 13). The numbers on the log-
axis in A and B represents pg/mL, while the numbers on the axis in C and D represents MFI.   
 
 
Mtb propagates a CD1a-hi moDC subset with similar properties as CD1a-lo 
moDCs by upregulating CD14 
To further examine the role of CD14-upregulation on Mtb-challenged moDCs, we 
used flow cytometry to assay the regulation (Fig. 3). Looking at immature moDCs, 
the two subsets based on CD1a-expression were clearly visible, but upon Mtb-
exposure the two subsets shifted into three: CD1a(lo)CD14(hi), CD1a(hi)CD14(hi) 
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and CD1a(hi)CD14(lo) (Fig. 3A). In contrast, stimulation with LPS kept the two orig-
inal DC populations, although CD14 was further downregulated. As IL-4 was previ-
ously reported to be responsible for downregulation of CD14,172 and were left out of 
the medium during culture with LPS and Mtb (to avoid non-physiological bias), we 
also assayed the phenotype of moDCs left unstimulated for 24 hours to judge for 
CD14 shifting. In the unstimulated moDCs, three populations were apparent like for 
Mtb-challenged cells, but the CD14-expression was lower on unstimulated DCs com-
pared to Mtb-stimulated DCs. Notably, the data illustrates that Mtb drives a polariza-
tion of moDCs that resembles that of unstimulated moDCs more than that of LPS, the 
latter exemplifying a prototypic Th1-promoting response type.    
 
We also assayed the different subsets for CCR2 and CCR5 expressions to define the 
chemoattractive profile of cells upon Mtb exposure (Fig. 3B). Interestingly, the 
CD1a(hi)CD14(hi) moDC subset had a similar CCR5 profile as the 
CD1a(lo)CD14(hi) moDCs after Mtb exposure, while the CD1a(lo)CD14(hi) subset 
expressed more CCR2. CCR7-expression was not modified in any of the subsets by 
Mtb stimulation (data not shown). The CD14(intermediate)CD1a(lo) moDC-subset 
found after LPS exposure displayed a CCR-profile similar to the two CD14-hi subsets 
induced by Mtb, while the CD1a(hi)CD14(lo) subsets derived by Mtb or LPS activa-
tion also resembled each other besides from a tendency to a higher CCR5 expression 
on LPS activated moDCs (Fig. 3B). Another interesting finding for the Mtb-induced 
CD14-hi moDC subsets was an upregulation of CD16 expression, which was also 
apparent for LPS-activated moDCs (Fig 3B).  
 
To examine if the CD14-hi moDC subset would affect cytokine production, we isolat-
ed CD1a-hi immature moDCs before stimulating with Mtb, measured the percentage 
of CD14(hi) moDCs induced by Mtb, and correlated this number to the levels of cy-
tokines produced from Mtb-challenged CD1a-hi moDCs (Fig. 3C). Our data showed a 
clear inverse correlation between the number of CD14-hi moDCs induced by Mtb 
within the purified CD1a-hi population and the level of IL-12 family cytokines and 
IL-1#; generally, the higher the CD14-hi fraction, the lower production of IL-12 fami-
ly cytokines and IL-1#. In line with this, the level of CD14-hi moDCs within the 
CD1a-hi moDC population also influenced the level of IFN-! produced by CD4+ na-
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ïve T cells co-cultured with moDCs (Fig. 3D). Production of IL-6 and IL-10 did, 
however, not seem to be affected by the Mtb-induced regulation of moDC subsets 
(Fig. 3C). Collectively, the data suggested a regulatory function of Mtb on moDCs 
resulting in increased CD14-hi expression, reduced IL-12 family cytokines, and di-
minished IFN-! levels in CD4+ T-cells. 
 
Figure 3: Induction of CD1a(hi)CD14(hi) moDCs by Mtb. A) Multicolor flow cytometry was used 
to assay difference in expression of CD14, between CD1a-lo and CD1a-hi immature moDCs, and 
moDCs stimulated with Mtb, LPS or left unstimulated. B) Flow cytometric characterization of Mtb- 
and LPS-stimulated moDCs. The color of the gate in the leftmost graph corresponds to the colors on 
the histograms to the right. C) CD1a-hi purified (>92%) were stimulated with Mtb, and assayed for 
CD14-expression by flow cytometry and cytokine production by ELISA. Correlation analysis between 
the number of CD1a(hi)CD14(hi) moDCs and cytokines produced are displayed. D) CD1a-hi purified 
moDCs containing various amounts of CD14-hi cells were co-cultured with T cells for 6 days. IFN-! 
was assayed by ELISA, and correlated to %CD1a(hi)CD14(hi) moDCs. Correlation analysis was done 
by a Spearman correlation test (n = 7-8).  
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PGN and ManLAM partly promotes the CD1a(hi)CD14(hi) moDC subset 
Mtb consists of a range of pathogen-associated molecular patterns (PAMPs), of which 
two of the most prominent are PGN and ManLAM. Therefore we sought to test if one 
or both of these PAMPs were responsible for the upregulation of CD14 in the CD1a-
hi moDCs (Fig. 4). PGN-challenge of CD1a-hi moDCs resulted in distribution of the 
moDCs into two CD14-hi populations in a manner similar to Mtb, while ManLAM 
skewed the populations alike unstimulated moDCs (Fig. 4A). However, simultaneous 
stimulation with ManLAM and PGN induced a more profound increase in the overall 
CD14(hi) population in moDCs from most donors (Fig. 4A-B). ManLAM has previ-
ously been shown to increase IL-10 and decrease IL-12p70 production in LPS-
triggered moDCs.22,26 Therefore we speculated whether the regulatory increase in 
CD14-hi moDCs could explain these findings. To test this, we measured the cytokines 
produced by CD1a-hi moDCs stimulated with PGN and the combination of PGN and 
ManLAM (Fig. 4C, E). At the same time, we used multi-color flow cytometry to test 
if ManLAM induced any noticeable differences in the display of surface markers on 
moDCs (Fig. 4D-E). The differences in cytokines and surface markers were ordered 
according to the largest effects (Fig. 4E). Of the 6 cytokines tested, only IL-12p70 
was consistently downregulated by ManLAM, and in general we observed great var-
iations in cytokine levels induced by individual donor CD1a-hi moDCs (Fig. 4C). IL-
1#, IL-6, IL-10, IL-23, and IL-27 were diversely regulated with some donors showing 
an increased expression, and others showing a decreased. ManLAM single simulation 
did not induce any cytokine production above detection level (data not shown). On 
the level of surface display of proteins (Fig. 4D, E), the two CLRs MR and DC-SIGN 
were found to be slightly reduced by ManLAM. CD40, CCR7, CD86, PD-L1, and 
HLA-DR also showed to be downregulated by ManLAM in most donors. CCR5 was 
regulated both up and down in a donor-dependent fashion. CCR2, CD16, and CD14 
were upregulated for most of the donors, with CD14 having the highest average up-
regulation of all assayed cytokines and markers. Thus, our data demonstrate that Mtb-
derived PGN and ManLAM collectively modify moDCs to program the Mtb-
promoted CD14-hi, IL-12p70-low phenotype.  
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Figure 4: Role of PGN and ManLAM in CD1a(hi)CD14(hi) moDC induction. moDCs were stimu-
lated with Mtb-derived PGN and ManLAM alone or in combination for 24 hours, and analyzed by flow 
cytometry (A, B, D & E) and ELISA (C & E). A) Representative flow cytometry plot for the division 
of moDCs according to CD1a- and CD14-expression patterns. The numbers in each gate represents the 
frequency inside the specified gate. B) Number of CD14-hi moDCs within the CD1a-hi gate for all 
donors (n = 8). C) Level of cytokines produced by PGN-single stimulation of CD1a-hi moDCs (left) or 
when combined with ManLAM (right). D) Representative flow histograms for ManLAM-mediated 
changes in PGN-induced phenotype of CD1a-hi moDCs. E) Collected ManLAM-mediated fold chang-
es in PGN-induced phenotype for all assayed surface markers and cytokines ordered by increasing 
positive fold change. Each dot represents one donor, and the error bars represents standard deviation. 
Data in B was tested for statistical significance by a repeated measures ANOVA, ***p<0.001. 
 
IFN-! but neither IL-17A nor IL-22 inhibits induction of CD1a(hi)CD14(hi) in 
Mtb-challenged moDCs 
!(T cells has been shown to produce the cytokines IFN-!, IL-17A and IL-22 in re-
sponse to Mtb-challenge.173 To test if these three cytokines would modulate the induc-
tion of CD14-hi moDCs, we stimulated CD1a-hi DCs with Mtb alone or in combina-
tion with each of these cytokines (Fig. 5). IL-17A and IL-22 did not modulate the 
generation of the CD1a(hi)CD14(hi) moDCs induced by Mtb (Fig. 5A). IFN-! on the 
other hand, almost completely inhibited the generation of Mtb-induced CD14-hi 
moDCs, resulting in a distribution of the moDCs into two subsets dispersed like those 
induced by LPS (Fig. 5A, B). IFN-! added as a single stimulus also inhibited the in-
cubation-induced generation of intermediate CD14 expression seen for unstimulated 
moDCs. IL-17A and IL-22 did not modify cytokine production from Mtb-activated 
moDCs, while IFN-! modulated the production of most of the cytokines assayed (Fig. 
5C & E). Most remarkably was the enormous increase in IL-12p70 production by 
IFN-! addition, but IL-23 and IL-27 were also consistently increased in all donors. IL-
6 was upregulated in most donors, while IL-1# was less constantly regulated amongst 
individual donors. IL-10 was also affected to a large extent, resulting in lower levels 
when IFN-! was added. A range of surface markers was also assayed for modulation 
by IFN-! (Fig. 5D-E). In addition to the extensive CD14-downregulation, CD16, 
CCR5, and CCR2 were also downregulated, but to a lesser extent. MR and CCR7 
were not modulated by IFN-!, while HLA-DR, PD-L1 DC-SIGN, CD40, and CD86 
were increased. None of these markers were modulated by IL-17A or IL-22 (data not 
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shown), therefore suggesting that moDCs do not respond to IL-17A and IL-22, as 
opposed to IFN- !.  
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Figure 5: Role of IL-17A, IL-22, and IFN-! on induction of CD1a(hi)CD14(hi) moDCs. moDCs 
were stimulated with Mtb and recombinant IL-17A, IL-22, and IFN-! at 100 ng/mL alone or in the 
combination of Mtb + recombinant cytokine for 24 hours, and analyzed by flow cytometry (A, B, D & 
E) and ELISA (C & E). A) Representative flow cytometry plot for the division of moDCs according to 
CD1a- and CD14-expression patterns. The numbers in each gate represents the frequency inside the 
specified gate. B) Number of CD14-hi moDCs within the CD1a-hi gate for all donors (n = 8). C) Level 
of cytokines produced by CD1a-hi moDCs after Mtb-single stimulation or in combination with one of 
three recombinant cytokines. D) Representative flow histograms for IFN-!-mediated changes in Mtb-
induced phenotype of CD1a-hi moDCs. E) Collected IFN-!-mediated fold changes in Mtb-induced 
phenotype for all assayed surface markers and cytokines ordered by increasing positive fold change. 
Each dot represents one donor, and the error bars represents standard deviation. Data in B was tested 
for statistical significance by a repeated measures ANOVA, ***p<0.001. 
 
  
2.5 Discussion 
Various subpopulations of DCs are known to co-exist in human tissues and may arise 
based on different progenitors, combined with a great plasticity within seeded DCs. 
Of current importance, both CD1a+ and CD1a- DCs are demonstrated to reside within 
human lungs.111,114,174,175 Recent reports suggest that some of these DCs might derive 
from monocytes,115,176 suggesting an in vivo relevance for moDCs in response to lung 
infections such as Mtb. Mtb single-stimulation of moDCs in vitro has been reported to 
induce close to no IL-12p70,28,55–57 and it is believed that IFN-! is needed for moDCs 
to produce IL-12p70 in response to Mtb.28 The present data can help to explain the 
low level of IL-12p70 in Mtb-activated moDCs by demonstrating that mainly CD1a-
hi moDCs induces IL-12p70 secretion. Furthermore, Mtb was shown to possess 
PAMPs that regulates the plasticity of these moDCs towards a phenotype with inverse 
display of high level CD14 expression and low level IL-12p70, thereby repressing 
propagation of IFN-!-producing CD4+ T-cells. Intriguingly, this phenotypic shift in 
Mtb-challenged moDCs was observed to be fully inhibited by IFN-! treatment, there-
fore suggesting that the role for IFN-! in boosting IL-12p70 is partly to inhibit gen-
eration of this CD1a(hi)CD14(hi) moDC subset. 
 
The combination of Mtb-derived PGN and ManLAM was partially responsible for 
this phenotypic shift in moDCs, and therefore it is possible that other microorganisms 
employing the same pattern recognition receptors could induce similar immune 
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modulations. Mtb PGN consists of MDP and !-D-glutamyl-meso-diaminopimelic acid 
(iE-DAP).177 MDP is a ligand for the intracellular sensor NOD2,178 while iE-DAP is a 
ligand for NOD1.179 TLR2 also recognizes PGN by virtue of embedded lipoproteins 
such as LpqH, LprG, LprA, and PhoS1 for Mtb.45 Most Gram-positive bacteria con-
tains MDP and the TLR2-triggering ligand lipoteichoic acid (LTA), while NOD1-
triggering is only promoted by selected Gram-positive bacteria.179 In contrast, most 
Gram-negative bacteria trigger all three receptors, but concurrently trigger TLR4 by 
virtue of LPS, and thereby induce high IL-12p70 production.180 Considering the phe-
notype of Mtb-activated moDCs it seems like the non-canonical TLR4 ligands present 
in Mtb53,54 does not hold much stimulatory potential for moDCs, as a combined liga-
tion of these with TLR2 and NOD1/2 would be expected to boost IL-12p70 similar to 
Gram-negative bacteria. Bacillus subtilis and Listeria monocytogenes are examples of 
two Gram-positive bacteria expressing ligands for all three receptors, while lacking 
TLR4-ligands. However, these two bacteria additionally express the TLR5-ligand 
flagellin, which induces copious amounts of IL-12p70 in moDCs.97,181 It therefore 
seems likely that the specific combination of triggering mainly TLR2 and NOD1/2, in 
combination with certain CLRs, explains why Mtb is capable of repressing IL-12p70 
production, and thereby evade immune clearance. 
 
In contrast to PGN and Mtb, the prototypic IL-12p70-inducing stimuli LPS lead to 
further downregulation of CD14 compared to immature CD1a-hi moDCs. An expla-
nation for this enhanced downregulation of CD14 by LPS could be due to receptor-
internalization upon linkage. One observation, however, argues against this, as IFN-! 
was also observed to mediate downregulation of surface CD14. A more likely mecha-
nism is receptor-shedding induced by endogenous enzymatic activity, which has been 
demonstrated when monocytes were stimulated with LPS or IFN-!.182 It has been 
speculated that the physiologic role of CD14 shedding is to generate soluble CD14 
needed for CD14- lymphocytes to respond to LPS.183 It could also be speculated that 
the role of CD14-shedding or surface CD14 downregulation in the IL-12p70-
producing moDC subset could be to limit an exaggerated immune response, in the 
sense that a cell already primed to produce IL-12p70 does not need to sense more LPS 
from the surroundings. An explanation for why CD1a-lo and CD1a(hi)CD14(hi) 
moDCs upregulate CD14 could be to sensitize these DCs to LPS-triggered apoptosis 
of terminally differentiated DCs, as described for murine DCs.184 If this hypothesis 
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were true, it would also mean that the downregulation/shedding of CD14 would imply 
extended cell life to the CD1a(hi)CD14(lo) DC subset.   
 
In addition to the currently identified linkage between surface CD14 and IL-12p70 
production, the present data furthermore suggest that there is a linkage between 
CD40/CD86 expression and IL-12p70 production. Three points of evidence supports 
this notion: 1) CD1a-hi moDCs expresses IL-12p70, CD40, and CD86 at the highest 
level, 2) ManLAM inhibits CD40 and CD86 expression, as well as IL-12p70 produc-
tion by PGN-activated CD1a-hi moDCs, and 3) IFN-! boosts both CD40/CD86 ex-
pression levels, and IL-12p70 production by CD1a-hi moDCs. Since CD40 and CD86 
are both co-stimulatory molecules during Ag-presentation, this could indicate that the 
highly-IL-12 family cytokine-producing moDCs are more prone to have proper inter-
action with naïve T cells, as demonstrated in a murine model system.185  
 
CD1 molecules are structurally similar to MHC class I molecules, and is used to pre-
sent lipids and glycolipids to T cells, and therefore play an important role in the im-
mune response towards Mtb.186 By inducing a subset of moDCs that has the ability to 
present Mtb-derived glycolipids (identified by CD1a-hi), but which at the same time 
lacks IL-12 family production and the ability to promote high level IFN-!-production 
in CD4+ naïve T-cells (the CD14-hi subset), it appears that Mtb possess an ability to 
prime the immune system insufficiently. This phenomenon may be causative for the 
inadequate clearance of Mtb within lungs of infected individuals, but will require ad-
equate in situ justification in future analysis. If moDCs has an in vivo relevance as 
reported by Varol et al. and Cheong et al.,115,176 our data on CCR expression levels 
moreover suggest that only the CD1a(hi)CD14(lo) moDCs would migrate out of the 
lungs, by virtue of low CCR5 and CCR2 expression.187–189 Likewise, it can be specu-
lated that the CD1a-lo and CD1a(hi)CD14(hi) moDC subsets remains situated within 
the lungs, because of the lack of CCR5 downregulation. The role of these DCs could 
be to limit excessive immune response by virtue of the observed higher PD-L1 and 
CD16 expression levels. PD-L1 has been associated with tolerogenic DCs,190 and sig-
naling through CD16 has been shown to inhibit TLR4-mediated IL-12p70 produc-
tion.191  
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In previous studies by others, it has not been emphasized that CD1a is differentially 
expressed on moDC preparations from different donors, but when looking through 
published data it is apparent that the CD1a-lo DC population is indeed present in 
some studies, as exemplified by the tail on the CD1a-histograms in these 
studies.107,170,192,193 A few years ago a couple of research groups started reporting 
about CD1a- moDCs generated during standard differentiation.194,195 These cells most 
likely correspond to the DCs we identify here as being CD1a-lo. For instance, like the 
present CD1a-lo moDCs, the CD1a- moDCs were characterized as having a higher 
expression of MR compared to the CD1a+ moDCs.194 One of the most important find-
ings for the CD1a- moDCs was their diminished ability to produce IL-12p70, which 
also corresponds with our findings. Besides from CD1a, moDCs also express CD1b, 
CD1c, and CD1d. These molecules were not included in our studies, because a previ-
ous report by Cernades et al.195 demonstrating that these CD1-markers in contrast to 
CD1a were expressed at the same level on all moDCs (both CD1a- and CD1a+).  
 
The different levels of CD1a-hi moDCs generated using the same culture conditions 
for a range of donors were quite curious, and we therefore examined the interference 
from several factors that could explain these differences. IL-10 has been reported to 
inhibit CD1a-expression on moDCs,169 and recently it was suggested that within the 
CD14+CD16+ cell population a small blood DC population exists (named DC-10) 
that are natural producers of IL-10.168 Therefore we analyzed the culture medium for 
an IL-10 contamination, but only found very small amounts, which furthermore did 
not correlate with the number of CD1a-hi DCs generated, or the amount of Mtb-
induced IL-12 family cytokines (Fig. S1). Given that a possible IL-10 production by 
DC-10s could quickly be taken up by the cultured cells, and therefore not be found in 
the culture medium, we also FACS-sorted the monocytes in order to get completely 
rid of CD14+CD16+ monocytes and DC-10s. In contrast to the hypothesis that these 
cells might decrease the amount of CD1a-hi DCs, we found that after removal of 
CD16+ monocytes the number of CD1a-hi DCs was either at the same level or at a 
lower level than the DCs generated from the mixed population of monocytes (Fig. 
S2), thus neglecting this hypothesis. It has also been suggested that too little IL-4 or 
GM-CSF would affect differentiation into DCs,196 so we tested the effect of increas-
ing the concentration of these cytokines on the final CD1a-hi yield. In contrast to this 
prior notion, we did not observe any effect on the number of CD1a-hi DCs by increas-
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ing the concentration or the ratio between IL-4 and GM-CSF (Fig. S3). The differen-
tiation into CD1a-hi moDCs may of course be influenced by the recombinant cyto-
kines used, and the specific medium composition, including the source of the FBS 
used. We always select every lab batch of FBS based on several factors including 
LPS-induced IL-12p70 levels, but other yet unknown exogenous factors may be more 
determinative for the resulting CD1a-display, if not the donor itself. Other groups 
have also reported differences in the level of CD1a-expression on moDCs generated 
from different donors. In a study by Gogolak et al.,194 the same donors were tested 
twice to assay if in vivo-relevant regulatory pathways play a role in the various levels 
of CD1a. The authors only observed a ±5% change in CD1a+ moDCs when blood 
was drawn from the same donor at different times. This therefore suggests that the 
donor cell response in the in vitro culturing system is relatively stable, but greatly 
variable in-between donors, given that the range of CD1a-hi moDCs was 25-96% in 
our study and 0-100% in the study by Gogolak et al. The ability of Mtb to induce two 
different CD1a-hi subsets separated by CD14-expression, also varied extensively be-
tween donors (range 7.4-75.6%, n = 8) in the present study. It could therefore be sug-
gested that the ability of monocytes and moDCs to differentiate into different subsets 
might be an intrinsically-encoded capacity within these cells that may be regulated at 
the gene level rather than by culture-dependent factors. The data presented here might 
help to explain why the capacity to develop protective immunity against mycobacteria 
is heterogeneously distributed among human beings,197–199 but further in vivo studies 
are needed to make firm conclusions. 
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Figure S1: Effect of IL-10 present in culture medium on DC differentiation. moDCs were generat-
ed by the standard procedure. Prior to harvesting DCs at day 6, the supernatants of the culture medium 
were harvested and assayed for IL-10 by ELISA. The IL-10 contents were correlated to A) % CD1a-hi 
DCs assessed by flow cytometry and B-D) Mtb-induced IL-12 family cytokine production using 
Spearman’s correlation test (n = 6). The line in the diagrams is the trend line shown for easier visual 
interpretation.  
 
 
Figure S2: Effect of CD16+ monocytes on DC differentiation. A) Monocytes were enriched by 
CD14-positive selection followed by i) further purification of CD14+CD16+ monocytes, or ii) deple-
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tion of CD14+CD16+ monocytes by cell sorting. The purity of the sorted populations was assayed by 
flow cytometry. Numbers in the FACS plots represents the percentage of cells inside the specified 
gates. After sorting, monocytes from i) and ii) were differentiated for 6 days, and assayed for CD1a 
expression by flow cytometry. The graph shows data from one representative experiment out of three. 
B) Correlation between the percentage of CD1a-hi DCs at day 6 and percentage of CD16+ monocytes 
in culture medium at day 0. Each dot represents one donor. Data was tested for a Gaussian distribution 
using the D’Agostino & Pearson omnibus test and correlation analysis was done by Pearson’s correla-
tion test (n = 16).  
 
 
Figure S3: Effect of IL-4 and GM-CSF on DC differentiation. Monocytes were cultured in the 
indicated concentrations of IL-4 and GM-CSF for 6 days in order to differentiate into DCs. Expression 
of CD14 and CD1a on monocytes and moDCs from the same donors was assessed by flow cytometry. 
Numbers in the FACS plots represents the percentage of cells counted within the specified gates. Cells 
from donor A and B were isolated on the same day, and are representative of two similar experiments. 
 
In summary, we have here demonstrated how Mtb exploits plasticity in moDCs to 
evade production of IL-12p70 needed for Th1-priming, and how the phenotype was 
fully recoded by exogenously administered IFN-!. 
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3 Isolation of IL-12p70-competent human monocyte-
derived dendritic cells  
Authors  
Jonas N. Søndergaard & Susanne Brix 
 
3.1 Abstract 
Diverse methodologies ranging from experimental immunological studies to immuno-
therapy involve the application of human monocyte-derived dendritic cells (moDCs). 
Considerable donor-dependent variations in the moDC production of IL-12p70 affect 
the outcome of these methodologies. It has been shown that moDCs generated under 
standard conditions develop into two subsets based on CD1a-expression with the 
CD1a+ moDCs being the main IL-12p70 producers. This has however not been gen-
erally accepted, which we show here is because the subset described as CD1a-
negative does express CD1a, but at a lower level than the other subset. We further 
characterize the phenotype of these two subsets, showing that the CD1a-hi subset has 
a greater immunogenic phenotype, making this subset more suitable for immunother-
apy. The two subsets have previously been separated by cell sorting, but as this tech-
nique is not available to many laboratories and has incompatibility with clinical set-
tings, a more widely useable technique is warranted. Therefore we tested if magnetic-
activated cell sorting is useful for the purpose, and show that it is possible to isolate 
IL-12p70-competent CD1a-hi moDCs to a <92% purity, irrespective of the starting 
purity.  
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3.2 Introduction 
Monocytes have for many years been differentiated into dendritic cells (DCs) in vitro 
for the study of DC biology and utility in treatment of cancer.200 One of the most stud-
ied DC-derived cytokines is IL-12p70 because of its importance in driving Th1-
responses needed to amplify CD8+ T cell-mediated killing of tumor cells and intracel-
lular infections.72 Ever since the first report on the generation of immature DCs with 
good Ag-presentation capabilities using a combination of IL-4 and GM-CSF, mono-
cyte-derived DCs (moDCs) has been described as CD1a-expressing.107 Later it was 
shown that perturbed culture conditions induces the generation of CD1a-negative 
moDCs, which are not able to produce IL-12p70.201 Certain research groups have 
reported that moDCs generated under standard conditions using FBS194,195 or autolo-
gous human plasma202 develops into both CD1a+ and CD1a- moDCs. Like the previ-
ously described CD1a- moDCs generated under perturbed culture conditions, the 
moDCs generated under standard conditions were largely incapable of producing IL-
12p70.  However, since most other research groups have reported that their moDC 
preparations expresses CD1a on all cells, this idea of a moDC subset lacking the abil-
ity to produce IL-12p70 generated under standard conditions has not been generally 
accepted. In this technical note we clarify that all moDCs generated under standard 
conditions express CD1a, but with a great variability in the levels of CD1a-hi and 
CD1a-lo cell subsets, influencing the capability of production of IL-12p70 and other 
cytokines important for Th-differentiation.  
 
Previously CD1a- and CD1a+ moDCs have been isolated by fluorescence-activated 
cell sorting. The advantage of this is that it is possible to get a very high purity, but 
the downside is that it is time-consuming, and tends to be harsh on the DCs as com-
pared to isolation using magnetic-activated cell sorting (MACS). Moreover, MACS is 
adaptable to clinical research settings. Therefore we tested whether it would be possi-
ble to use an existing CD1a-MACS kit intended for the isolation of Langerhans cells 
to purify the CD1a-hi moDCs from the CD1a-lo moDC population. The methodology 
is worthwhile for isolation of IL-12p70-competent DCs to be used for enhancing the 
effectiveness of cancer immune therapy as well as for a diversity of basic immunolog-
ical research, e.g. cellular signaling studies were homogenous cell subsets are critical 
for understanding the molecular processes.   
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3.3 Materials and methods 
Reagents. The following reagent was obtained through the NIH Biodefense and 
Emerging Infections Research Resources Repository, NIAID, NIH: Mycobacterium 
tuberculosis, strain H37Rv purified peptidoglycan (PGN), NR-14853. E. coli LPS 
(O26:B6) was purchased from Sigma Aldrich. The following anti-human Abs were 
used in the studies: CD1a/PE (clone# HI149), HLA-DR/v500 (G46-6), CD86/v450 
(2331(FUN-1)), PD-L1/PE-Cy7 (M1H1), DC-SIGN/FITC (DCN46), MR/APC (19.2)  
(all from BD), CD14/PE-Cy7 (61D3), (eBioscience), CD16/FITC (3G8), 
CD40/PerCP-Cy5.5 (5C3) (both from Biolegend). 
 
Human blood samples. Human buffy coats were acquired from the blood bank at the 
Copenhagen University Hospital (Rigshospitalet) collected from anonymous healthy 
donors. Blood samples were handled in accordance with guidelines put forward in the 
“Transfusion Medicine Standards” by the Danish Society for Clinical Immunology 
(www.dski.dk). The buffy coats were obtained from 450 mL whole blood donations 
in citrate phosphate dextrose anticoagulant. The whole blood was fractionated to sep-
arate the majority of erythrocytes and plasma. The buffy coat contains approximately 
90% of the leukocytes from the 450 mL of blood, and was used within 5.5 hours upon 
blood draw. 
 
Cell purification and culture. PBMCs were isolated from human buffy coats by Fi-
coll-Paque (GE Healthcare) density centrifugation. The PBMCs were labeled with 
magnetic-particle linked CD14 Abs (Miltenyi) and isolated using MACS (Miltenyi). 
Cells were cultured in RPMI 1640 (Lonza) containing 2% (all percentages represent 
volume to volume) L-glutamine (Lonza), 10% fetal bovine serum (FBS, Lonza), 1% 
penicillin/streptomycin (Lonza), 50 &M #-ME (Sigma-Aldrich) and 10 mM HEPES 
(Lonza). Cells were kept in a humidified 37°C, 5% CO2 incubator. For differentiation 
of monocytes into immature DCs, the medium was supplied with 20 ng/mL ('160 
U/mL) recombinant human GM-CSF and 30 ng/mL ('150 U/mL) recombinant hu-
man IL-4 (both CellGenix). The cells were grown in polystyrene 6 well plates (Nunc) 
at a concentration of 2*106/mL. Monocyte cultures were supplied with fresh medium 
containing fresh GM-CSF and IL-4 on day 3, and non-adherent immature moDCs 
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were harvested on day 6. Immature moDCs were plated at a cell concentration of 
106/mL and stimulated with 500 ng/mL LPS and 10 &g/mL PGN (final concentra-
tions) determined as optimal concentrations in dose-response experiments (data not 
shown). 
 
Enrichment of CD1a-hi moDCs. Immature moDCs were carefully harvested on day 
6 and washed 2X in PBSE-buffer consisting of PBS (Lonza), 2 mM EDTA (Sigma-
Aldrich), and 2% FBS (Lonza). Cell pellet containing 25-50*10^6 immature moDCs 
were resuspended in residual PBS (~300 &L) and added 100 &L CD1a-Abs bound to 
magnetic beads (Miltenyi catalogue# 130-051-001), followed by a 30 min incubation 
at 4°C. Labeled cells were washed 1X in PBSE and resuspended in 3 mL degassed 
PBSE. MACS was performed by standard-procedure as described in the manufactur-
er’s instructions, but in order to avoid column-blockage, degassed PBSE was used for 
all steps. The CD1a-lo fraction was collected as flow-through and the CD1a-hi frac-
tion as column-bound. Before collection, the positive fraction the column was rinsed 
3 times with 3 mL degassed PBSE.  
 
ELISA. ELISA was performed according to the manufacturer’s instructions. Superna-
tants of stimulated and unstimulated moDCs were harvested after 24 hrs and kept at -
40°C until analysis. The following ELISA kits were used in this study: human IL-12 
and IL-27 (both R&D Systems) and IL-23p19p40 (eBioscience). 
 
Flow cytometry. Flow cytometry was performed according to standard procedures. 
The wash and staining buffer consisted of PBS with 1% FBS and 0.1% Na-azid (Sig-
ma-Aldrich). Before staining, the cells were incubated for 10 minutes in staining 
buffer with 2% allogeneic human AB plasma (Rigshospitalet) to limit non-specific 
binding of Abs.  
 
Statistics. All data was tested for a Gaussian distribution using a D’Agostino & Pear-
son omnibus test. Data that did not follow a Gaussian distribution were either log-
transformed or analyzed by a non-parametric statistical method. Statistical signifi-
cances were based on a student’s paired t-test or a Wilcoxon matched-pairs signed 
rank test. Analysis was conducted using Prism 5 (Graphpad Software). 
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3.4 Results and discussion 
The level of IL-12p70 produced by moDCs upon stimulation tends to vary considera-
bly between donors. As expression of this cytokine is fundamental for various immu-
nological settings such as DC immunotherapy and experimental studies of diverse 
microbial-induced phenotypes, we here demonstrate a method useful for isolation of 
pure IL-12p70-competent moDCs. Initially, we examined the reason for the contra-
diction in reports relating to the presence, or not, of CD1a-negative moDCs within in 
vitro-generated moDC preparations. By comparing the expression of CD1a on mono-
cytes and moDCs from the same donors, we found that all moDCs expresses CD1a 
(Fig. 1a), but at two distinct levels, reflecting the two moDC populations that would 
correspond to the formerly reported CD1a- and CD1a+ subsets.194,195 We analyzed 
both immature moDCs and LPS-activated moDCs (the latter is shown in fig. 1a), but 
activation did not alter the level of CD1a significantly. It could be argued that the 
CD1a-lo moDCs have a higher unspecific binding of the CD1a-Abs compared to the 
monocytes, as the LPS-activated moDCs are bigger. However, immature moDCs, 
which has a size closer to monocytes, also displayed the CD1a-lo moDC subset as 
having a much higher MFI than the monocytes they originated from (on average 53-
fold increase in MFI, n = 11). Furthermore, the staining buffer was added 2% alloge-
neic human AB plasma, which should minimize unspecific binding significantly. 
Since all moDCs expresses CD1a, a more correct name would be CD1a-lo and CD1a-
hi moDCs. Using this enumeration, we gated on the two populations for a range of 
independent donors, and found that the numbers of CD1a-hi moDCs were distributed 
very heterogeneously in the assayed population (Fig. 1b).  
 
 
 
- 49 - 
 
Figure 1: Diverse expression of CD1a on moDCs. A) Monocytes and moDCs from the same donor 
were analyzed for CD1a-expression by flow cytometry. The dot plot is representative for 11 donors. 
The expression levels of the moDCs and monocytes are overlayed within the plot (i.e. no monocytes 
are present within the moDC preparations). B) MoDCs were gated into CD1a-lo and CD1a-hi express-
ing subsets, and the % of CD1a-hi moDCs plotted for each donor (n = 28). 
 
To further characterize the difference between the CD1a-lo and CD1a-hi moDCs, we 
gated on these two populations and compared a range of surface markers. At the im-
mature state the CD1a-lo moDCs expressed the highest levels of HLA-DR, CD86, 
PD-L1, MR, DC-SIGN, CD14 and CD16 compared to the CD1a-hi moDCs (Fig. 2a).  
In immature CD1a-hi moDCs, only CD40 was expressed at the highest level. We also 
examined the LPS-activated phenotype of the moDCs (Fig. 2b). After stimulation, the 
CD1a-lo subset still expressed the highest level of PD-L1, MR, CD14 and CD16, 
while HLA-DR, CD86 and DC-SIGN, in contrast to the immature state, were ex-
pressed either at a lower level or at the same level as the CD1a-hi moDCs. CD40 was 
still expressed at the highest level on the CD1a-hi moDCs after stimulation. One no-
ticeable observation for the immature DCs was the higher HLA-DR expression on the 
CD1a-lo subset. One explanation for this could be that during differentiation of mon-
ocytes into DCs some of the cells undergo apoptosis and is taken up by the DCs and 
therefore upregulate HLA-DR.203,204 One could argue that the CD1a-lo moDCs are 
DCs that has taken up these apoptotic bodies, but one observation in our culture sys-
tem clearly argues against this, as we usually obtained the lowest overall moDC num-
ber in cultures with the lowest percentage of CD1a-lo moDCs, and not the opposite. 
Therefore other factors than those pertaining to apoptotic regulation seem to be in 
play.  
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Figure 2: Characterization of differences in phenotype between CD1a-lo and CD1a-hi moDCs. 
Immature (A-B) and LPS-stimulated (C-D) moDCs were analyzed by flow cytometry and gated into 
two populations determined by CD1a-expression. Eight other surface markers were assayed and MFI 
values extracted. A and C: Each dot represents one donor, and the error bars represent standard devia-
tion. B and D: The ratio of expression on CD1a-hi versus CD1a-lo moDCs of each surface marker was 
calculated for each donor, and the average of all donors is plotted. The numbers on the y-axis denomi-
nates the CD1a-hi/CD1a-lo MFI ratio, and the dotted line represents equal expression level on the two 
subsets. Data were tested for a Gaussian distribution using a D’Agostino & Pearson omnibus test.  All 
surface markers except CD14 and CD16 for LPS-stimulated moDCs were analyzed for statistically 
significant differences by a student’s two-tailed paired t-test (n = 11-17). CD14 and CD16 were tested 
for statistical significance by a Wilcoxon matched-pairs signed rank test (n = 6). *p<0.05, **p<0.01, 
***p<0.001. 
 
Interestingly, we found that at the immature state the CD1a-lo subset had a high ex-
pression of CD86 and HLA-DR without high level CD40, which possibly could lead 
to a regulatory state of interacting T cells.185 Besides from having low IL-12p70 pro-
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duction, tolerogenic DCs are reported to have a high expression of PD-L1,190 which 
we also observed to be the case for the CD1a-lo moDCs. Another interesting observa-
tion for the CD1a-lo moDCs was the higher expression of CD16, as it has previously 
been reported that signaling through this receptor inhibits TLR4-mediated IL-12p70 
production.191 Based on these comparisons, it seemed apparent that the CD1a-lo 
moDC subset showed characteristics similar to those of tolerogenic DCs. Since both 
CD1a-lo and CD1a-hi subsets are present in all the moDC preparations generated for 
this study (n = 28), although to variable levels, it emerges that the protocols for exper-
imental moDC studies should be selected cautiously. It must be kept in mind that the 
two moDC subsets differ in functionality and therefore may impact the outcome of 
the immunotherapy or the experimental study differentially. However, whether or not 
the general protocol for moDC generation is applicable will depend on the objective 
of the study. If the goal of a study is to examine surface markers and cytokine expres-
sion levels upon TLR-induced activation, the standard protocol for moDC generation 
may be used, as long as the percentage of CD1a-hi moDCs is recorded per donor. For 
studies of intracellular cell signaling it is of vital importance to have as homogenous a 
cell population as possible in order to minimize background signaling, and therefore a 
post-differentiation isolation of e.g. pure CD1a-hi moDCs would improve the results. 
The ratio of CD1a-hi/CD1a-lo moDCs derived from each donor will also have major 
implications for cancer immunotherapy, as one could speculate that the injection of 
CD1a-lo moDCs would dampen the immune response against tumor-derived Ag in-
stead of strengthening it; this will be due to a low level of IL-12p70, and a high basal 
and matured expression level of PD-L1. One way to immediately improve cancer 
immunotherapy protocols would be to isolate the CD1a-hi moDC subset, and use this 
for treatment, instead of the current combination of CD1a-lo and CD1a-hi moDCs. 
Therefore we tested if it is possible to use MACS for isolation of the CD1a-lo and 
CD1a-hi moDC subsets. Figure 3A shows an example of cells from two donors iso-
lated on the same day. It is clear that the purity of the CD1a-hi moDCs are at a satis-
factory level above 92% (Fig. 3A and 3C, n = 10), while the purity of the CD1a-lo 
population is at an unacceptable level (e.g. 17% for donor Y). Besides from being the 
main IL-12p70-producers, the CD1a-hi moDCs also produced the other two IL-12 
family cytokines IL-23 and IL-27 at a higher level than the CD1a-lo moDC subset 
(Fig. 3B), further verifying the enhanced immunogenicity of this moDC subset. On 
average the technique gave a yield of 67% CD1a-hi moDCs compared to the maximal 
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number available after 6 days of differentiation (Fig. 3D). Therefore it must be con-
sidered whether purity or yield has the highest priority in each experimental setup, 
before adapting this protocol.  
 
Of notice is that we have used FBS in our culture system, which cannot be used for 
the generation of clinical-grade DCs, but exchanging FBS with autologous human 
plasma should make this procedure clinically adaptable. Given the ease, speed and 
greater sterility of the magnetic isolation procedure compared to cell sorting, this may 
be applicable right away for clinical testing of improved immunogenicity of tumor-Ag 
loaded CD1a-hi moDC preparations.  
 
 
Figure 3: Isolation of IL-12p70-competent moDCs by MACS. After 6 days of differentiation, imma-
ture moDCs were harvested and labeled with CD1a-Abs linked to magnetic beads. The CD1a-hi moDC 
population was subsequently isolated by positive selection by MACS, while the CD1a-lo population 
was collected as flow-through. A) Purity of the different populations was assessed by flow cytometry. 
Numbers in the FACS plots represent the percentage of cells counted within the specified gates. The 
graphs show examples of isolation of CD1a-hi and CD1a-lo moDCs from two donors out of 12. B) 
Cytokine production measured by ELISA in the culture supernatants after 24 hours stimulation with 
LPS or peptidoglycan (PGN) of the two purified moDC populations. The plot is representative for the 
only 2 donors giving a satisfactory CD1a-lo purity (>85%). The error bars represent standard deviation 
of duplicates. C) Purity of the CD1a-hi moDC population before and after MACS. Each dot represents 
one donor (error bars = SD, n = 12). D) Yield of CD1a-hi purified moDCs. The plot also shows starting 
monocyte number, total moDC yield, and the maximum CD1a-hi yield calculated by multiplying the 
percentage of CD1a-hi moDCs before MACS with the total number of moDCs. Each dot represents 
one donor (error bars = SD, n = 12).   
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4 Kinome-wide analysis of human dendritic cells to de-
duce pathways involved in M. tuberculosis-mediated 
Th17-bias 
Authors 
Jonas N. Søndergaard, Erwin M. Schoof, Rune Linding & Susanne Brix 
 
4.1 Preface 
In the final manuscript about Mtb’s interaction with moDCs the focus has been put on 
phosphorylation events induced in moDCs after Mtb exposure. This project is not yet 
finalized, as additional analysis of the kinome data, and verification in culture exper-
iments is needed. The kinome data presented in this chapter has been generated based 
on a ratio between the level of kinase-activation of Mtb- and LPS-stimulated moDCs, 
in order to see if any Mtb-specific kinases could be identified. Further analysis will 
include 1) comparing stimulated phosphopeptide-enriched samples to total peptide 
sample, thereby enabling identification of additional Mtb/LPS-activated kinases, and 
2) comparing all LPS-activated kinases to well-known signaling networks down-
stream of TLR4. Additional cell culture experiments will include verification of the 
role of the identified kinases in Mtb-DC interactions by using small molecule inhibi-
tors, siRNA knockdown, and phosphoflow. Since this is the first time ever that any-
one has used MS-based phosphoproteomics on human DCs, the finalized manuscript 
is intended for Nature letters. Therefore the manuscript has been prepared according 
to the guidelines of this journal, and hence has a different structure than the other pa-
pers included in this thesis.  
 
4.2 Abstract 
Dendritic cells (DCs) are at the frontline in the defense against the re-emerging path-
ogen M. tuberculosis (Mtb).35–37 They detect the infection at the lung mucosal surfac-
es and subsequently initiate the adaptive immune response necessary for clearance of 
the infection.17 At the very first contact, intracellular signaling cascades are induced, 
which will determine the phenotype of the DC, and ultimately shape how the immune 
response unfolds.148 Only small fragments of the signaling cascades are known, and 
studies have so far been biased towards well-known pathways.23,97–100,102–105 Here we 
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have for the first time used an unbiased kinome-wide approach to delineate the signal-
ing induced by Mtb in human DCs. Twenty one Mtb-specific kinases were identified, 
which currently hold unknown roles in the immune response towards Mtb, and hence, 
need to be validated in cell culture experiments. The signaling induced by Mtb medi-
ated an immune response directed at extracellular bacteria, as evidenced by a DC- and 
naïve CD4+ T-cell-phenotype biased towards Th17. Targeting the identified kinases 
might re-direct the immune response towards Th1-bias, thereby promoting clearance 
of latent Mtb. This could have therapeutic potential for the 2 billion people currently 
infected with this bacterium. 
 
4.3 Results and discussion 
The optimal immune response against an intracellular bacterium like Mtb includes an 
IL-12p70-driven Th1 response.71,72 Purified CD1a-high, IL-12p70-competent mono-
cyte-derived DCs were stimulated with Mtb and a prototypic IL-12p70-promoting 
bacterial stimulus (lipopolysaccharide, LPS). Interestingly, DCs stimulated with Mtb 
or LPS showed a very different cytokine response pattern (Fig. 1A). The prototypic 
Th1-inducing cytokine IL-12p70 was almost completely absent when DCs were stim-
ulated with Mtb (on average 81-fold less compared to LPS). Likewise, the Th1-
enhancing cytokine IL-2773,74 was induced on average 2.2-fold less by Mtb. In con-
trast, the Th17-promoting cytokines IL-1# and IL-2386 were induced on average 38-
fold and 6-fold higher by Mtb compared to LPS. IL-6, which has been shown to en-
hance Th17 differentiation,84 and the immunosuppressive cytokine IL-1075,76 were 
both induced at similar levels by the two stimuli. Collectively, the DC cytokine re-
sponse pattern suggests that Mtb promotes a Th17-bias, while LPS promotes a Th1-
bias. To verify that DC phenotypes corresponded with the predicted T cell pheno-
types, DCs were co-cultured with naïve CD4+CD45RA++ T cells isolated from al-
logeneic donors (Fig. 1B-C). Both extracellular and intracellular cytokine analysis of 
the DC-primed T cells showed that Mtb induces a stronger Th17-profile (7.5-fold 
extracellular, 1.7-fold intracellular) and a weaker Th1-profile than LPS (2.5-fold ex-
tracellular, 2.2-fold intracellular). Mtb furthermore induced a 5-fold higher IL-10 pro-
duction from the naïve T cells compared to LPS.  
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Figure 1: Mtb induces a DC phenotype promoting a Th17 bias. A) DCs were stimulated with LPS 
and Mtb or left unstimulated for 24 hours and supernatants were analyzed by ELISA. B-C) DCs were 
stimulated with LPS and Mtb for 6 hours, and subsequently co-cultured with allogeneic naïve 
CD4+CD45RA++ T cells for 6 days. Supernatants from the co-culture were harvested and analyzed by 
ELISA (B), and matured T cells were re-stimulated with PMA/ionomycin for 5 hours and analyzed by 
intracellular flow cytometry (C). The dot plot in (C) is representative of 8 donors, and statistics were 
conducted on all donors. Data were analyzed by a student’s paired t test (n = 8).  
 
At present, it is unclear if any surface markers on DCs particularly correlate with Th1 
or Th17 responses. To assay this, we examined if there was any difference in the ex-
pression of a range of surface markers between LPS (Th1-promoting) and Mtb (Th17-
promoting) (Fig. 2). Several of the assayed surface markers were regulated in the 
same manner by LPS and Mtb; HLA-DR, CD86, PD-L1 and CCR5. CD40 was more 
upregulated by LPS, which corresponds to a former report stating that CD40 upregu-
lation is needed for IL-12p70 production.185 The CLRs, MR and DC-SIGN were more 
downregulated by Mtb, which can be contributed to a ligation of these from Mtb-
derived ManLAM and PIM6.22,43,44 Interestingly, CD16, which has been shown to 
inhibit TLR4-mediated IL-12p70 production,191 was upregulated the most by Mtb. 
CCR7 was curiously downregulated by Mtb, which could be due to the specific strain 
of Mtb (H37Rv) used for the studies,205 or because of a general lack of CCR7 upregu-
lation in monocyte-derived DCs.206 A time course experiment showed that Mtb did 
not upregulate CCR7 to a higher level earlier than 24 hours (data not shown). Collec-
tively, it could be suggested that CD40 and CCR7 are linked to Th1-responses, while 
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CD16, MR, and DC-SIGN are linked to Th17 responses. However, additional Th1 
and Th17 promoting stimuli should be tested and compared to these results to make a 
firm conclusion.  
 
 
Figure 2: Differences in the DC surface marker phenotype between LPS- and Mtb-treatments. 
DCs were stimulated with LPS and Mtb or left unstimulated for 24 hours and analyzed by flow cytom-
etry. A) Representative pseudo-color dot plots from one donor out of 8. MFI values were extracted and 
used for statistical analysis. The level of statistical significance, represented by asterisks over the Mtb 
stimulation, is based on comparison to the LPS-induced phenotype (n = 8). B) The ratio of expression 
on Mtb- versus LPS-stimulated DCs of each surface marker, averaged over the individual ratios. The 
numbers on the ordinate represents the Mtb/LPS MFI ratio, and the dotted line represents equal expres-
sion level induced by the two stimuli. Data was analyzed by a repeated measures ANOVA with a Tuk-
ey post-hoc test or a Friedman test with Dunn’s post-hoc test. 
 
Mtb contains pathogen-associated molecular patterns that previously have been 
demonstrated to induce IL-12p70,28,53,54,163 thus arguing that Mtb actively inhibits IL-
12p70 production in DCs. In order to assay if regulation of IL-12p70 is happening 
before or after gene transcription, the expression of IL12A, encoding IL-12p35, which 
is one of the two heterodimers constituting IL-12p70, was assayed in a time-course 
experiment (Fig. S1). The data clearly demonstrated that Mtb did not induce any up-
regulation of IL12A, thus arguing that regulation of IL-12p70 is taking place pre-
transcriptionally. In contrast to IL12A, Mtb did induce upregulation of IL10.  
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Figure S1: qRT-PCR time-course for upregulation of IL12A and IL10. DCs were stimulated with 
LPS and Mtb or left unstimulated for the indicated amount of time. RNA was purified, and relative 
quantity (RQ) of IL12A (A) and IL10 (B) was determined by qRT-PCR on the basis of comparison to 
immature DCs harvested before initiating stimulations. Error bars represent SD for duplicates of sepa-
rately stimulated DC preparations.  
 
To obtain a better understanding of the processes of signaling involved in regulation 
of the IL-12p70 production in DCs by Mtb, a kinome-wide analysis was conducted. 
For comparison LPS was used because of its status as a prototypic IL-12p70-inducing 
stimuli. On average 356 phosphoepitopes were determined in the DCs after 30 
minutes of stimulation (n = 3, Table S1).  
 
Table S1: Numbers of regulated phosphoepitopes in all donors. 
 Mtb-specific Non-regulated LPS-specific 
Donor 1 47 268 12 
Donor 2 49 282 32 
Donor 3 55 286 38 
 
In a preliminary assessment of the data, we focused on identifying kinases that were 
specifically activated by Mtb in comparison to LPS (Fig. 3, Fig. S2). A threshold of 
one SD from the mean ratio was used to define up- or down-regulation. In general 
Mtb activated much more kinases than LPS, which may be attributed to triggering of 
several pattern-recognition receptors (NOD1/2, TLR2, MR, DC-SIGN) instead of 
triggering of just TLR4. Three donors were assayed, and using the employed thresh-
old, many of the assayed kinases did not overlap between donors (Table S2). The rea-
son behind the small number of kinases activated consistently between donors can be 
explained by the different genetic backgrounds, possible meaning that signal-
transduction is happening at different pace in individual donors. Different signaling 
cascades progressing from different pattern-recognition receptors triggered by Mtb 
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(NOD1/2, TLR2, MR, DC-SIGN) may also happen at different pace in individual 
donors. Therefore a time-study on a range of donors would be desirable to obtain the 
best understanding of the dynamics in signaling, and to enhance identification of 
which kinases are involved. Nevertheless, 21 kinases were identified to be specifically 
activated by Mtb in minimum 2 of the assayed donors, with 7 kinases being activated 
in all three donors (Table S2).  
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Figure 3: Identified and predicted kinases regulated by Mtb and LPS. DCs were stimu-
lated with Mtb or LPS for 30 min. Phosphopeptides were enriched by TiO2 and assayed by 
LC-MS/MS. Identified peptides for the two stimuli were compared to each other to identify 
Mtb- and LPS-specific kinase activity. Interactions with other kinases were predicted using 
SSB
C1orf38 
HMGN1 
BNIP3L
OXSR1 
PEA15 
HTT 
ACSS2 
PDCD4 
PPP1R3D 
WNK1 
MAP3K6 
NUMB 
AMPD2 
TP53I11 
SPN
OPTN 
NFKBIE 
LIMA1 
OGFR 
CBFB 
KLC1 RPLP2 
PGAM1 
PCYT1A 
PKM2 
CD44 CBX3 
MAP3K2 
HSPB1 
RPS6 
MYO18A
F11R 
CD40 
MAP3K3 
MAP3K5 
PRKAR2A 
PTPN7 
STX4 
NCK1 
PPP1R2 
APBA1 
MYH9 
SNAP23 
NCBP1 
BNIP2 
EIF4G1 
GIT1 
SEPT9 
TRPV2 
SEC62 
LYN
UBA1 
NAP1L4 
EEF1B2 HSP90AA1 
SSRP1 
NCLSEC31A 
API5 
CANX 
CLIP1 
PTPRC 
ITGA5 
HNRNPH1 
LASP1 
HN1
HDGF 
CCNY 
NUCB1 
RAPGEF1 
SIPA1 
PSD4 
DCP1B 
PRKCD 
DNAJC5 
RALBP1 
PDHA1 
VIM
JUNB
PALLD 
STMN1 
PTPN12 
NDRG1 
ARAP3 
MYO9B 
RIC8A 
RCSD1 
MAPK14 
AKAP13 
KTN1 
IGF2R 
RGS14 
SPAG9 
LSP1 
NDRG2 
ETV6 
MAPK1 
EVL
CAD 
PPP1R7 
LCP1 
TBC1D1 
ACLY 
TAOK3 KIAA0528 
NSFL1C 
COPB2 PSMD1 
SEPT2 
ARHGAP1 
PRKAR1A NUCKS1 
ZC3HC1 
EEF1D 
C11orf58 
PI4K2A 
SRSF3 LMNA 
LRRFIP2 
CDK7 
TRIM28 
GTF2I 
USO1 
HNRNPD 
CTNNA1 
TSC2 
ALDOA 
PGRMC1 
GSK3beta NEK3 
AMPKa2 
PKBbeta 
p70S6K 
PKBgamma 
CaMKIIbeta 
PLK3
MAPK1 
RIC8A 
PRKAR1A 
MAPK7 MAK
RSK4RSK1
RSK3
CaMKIIgamma 
PEA15 
RSK2
PLK4
RAF1
PSD4
PDHK1 TBC1D1 
PKAalpha 
GRK1 PLK1
SEC31A 
CK2a2 
HSP90AA1 GRK3 
GRK6 
GSK3alpha 
CK2alpha 
p70S6Kb 
TP53I11 
PKG1cGKI 
PKBalpha 
PKCepsilon 
PKCeta 
PKCzeta 
HIPK2 
SSB
HTT
PKG2cGKII 
HMGN1 
ACTR2B 
PLK2
CDK6 
CLK2 
CDK4 
CBFB
GTF2I 
SLK
MAPK14 
MAPK3 
CDK1 
CDK2 
CK1alpha 
SEC62 
DMPK2 
CK1epsilon 
CK1delta 
PKCalpha 
PAK2 
PKCbeta 
TGFbR2 
PKCtheta 
PKCiota F11R
PKCgamma 
PKCdelta 
RPS6
MYH9 
MRCKa 
BRAF
AuroraC 
PKD3 
! Mtb-specific activation
! LPS-specific activation
! Below threshold for regulation
! NetworKIN-predicted interaction
Size: activation ratio for Mtb/LPS
A)
B)
- 60 - 
NetworKIN. Identified kinases with no interactions are not displayed. A) Example of kinase 
network constructed from one donor. B) Isolated Mtb-activated kinases and directly-linked 
NetworKIN predictions.  
´
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Figure S2: Identified and predicted kinases regulated by Mtb and LPS in additional 
donors. DCs were stimulated with Mtb or LPS for 30 min. Phosphopeptides were enriched 
by TiO2 and assayed by LC-MS/MS. Identified peptides for the two stimuli were compared 
to each other to identify Mtb- and LPS-specific kinase activity. Interactions with other ki-
nases were predicted using NetworKIN. Identified kinases with no interactions are not dis-
played. 
 
Table S2: Mtb-specific activated kinases identified in minimum 2 donors. 
ID Full name Site # of donors 
MYH9 Myosin, heavy chain 9, non-muscle S1943 3 
HSP90AA1 Heat shock protein 90kDa $ (cytosolic), class A member 1 S385 3 
TP53I11 Tumor protein p53 inducible protein 11 S14 3 
SPN Sialophorin T341 3 
PEA15 Phosphoprotein enriched in astrocytes 15 S137 3 
RPS6 Ribosomal protein S6 S235 3 
EVL Enah/Vasp-like S333 3 
BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like S64 2 
PSD4 Pleckstrin and Sec7 domain containing 4 S1019 2 
SSB Sjogren syndrome antigen B S366 2 
TBC1D1 TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 S627 2 
U2AF2 U2 small nuclear RNA auxiliary factor 2 S79 2 
GTF2I General transcription factor IIi S823 2 
RIC8A Resistance to inhibitors of cholinesterase 8 homolog A S442 2 
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 S6 2 
HTT Huntingtin S1874 2 
PRKAR1A Protein kinase, cAMP-dependent, regulatory, type I, $ S83 2 
HDGF Hepatoma-derived growth factor S181 2 
KTN1 Kinectin 1 S75 2 
SRRM1 Serine/arginine repetitive matrix 1 S695 2 
TCOF1 Treacher Collins-Franceschetti syndrome 1 S1387 2 
 
The kinases assayed to be specifically activated by Mtb have not previously been 
linked with TLR/NOD/CLR-signaling and could therefore be interesting new find-
ings. The kinases might, however, also not play a role in IL-12p70 inhibition, and 
need to be validated before making any conclusions. The NetworKIN predicted inter-
actions could give clues whether the data holds validity or not. There were 47 kinases 
predicted to have interactions with the 7 kinases consistently activated by Mtb in the 3 
donors (Fig. 3B, Table S3). Among these was Raf-1, which previously has been 
shown activated upon DC-SIGN ligation,101 and hence could participate in Mtb-
induced signaling. In the study by Gringhuis et al.,101 Raf-1 was shown to induce IL-
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10, known to inhibit IL-12p70, and therefore the assayed kinases predicted to interact 
with Raf-1 might also play a role in IL-12p70 inhibition. Another predicted interac-
tion was MAPK3, better known as ERK1. ERK1 has also been associated with signal-
ing downstream of Mtb-activated pattern-recognition receptors, and shown to inhibit 
IL-12p70 production.97,99,102,103  
 
Table S3: NetworKIN-predicted kinases directly interacting with Mtb-specific activated kinases 
identified in all donors. 
ID Full name 
AMPKa2 5'-AMP-activated protein kinase catalytic subunit $-2 
AuroraC Aurora kinase C 
CaMKII# Ca2+/calmodulin-dependent protein kinase II# 
CaMKII! Ca2+/calmodulin-dependent protein kinase II! 
CDK4 Cyclin-dependent kinase 4 
CDK6 Cyclin-dependent kinase 6 
CK1$ Casein kinase 1$ 
CK1( Casein kinase 1( 
CK1epsilon Casein kinase 1 epsilon 
CK2a2 Casein kinase 2a2 
CK2$ Casein kinase 2$ 
CLK2 CDC-like kinase 2 
DMPK2 Dystrophia myotonica protein kinase 2 
GRK3 G-protein-coupled receptor kinase 3 
GRK6 G protein-coupled receptor kinase 6 
GSK3$ Glycogen synthase kinase 3$ 
GSK3# Glycogen synthase kinase 3# 
HIPK2 Homeodomain interacting protein kinase 2 
ICK Intestinal cell (MAK-like) kinase 
MAK Male germ cell-associated kinase 
MAPK3 Mitogen-activated protein kinase 3 
MRCKa Myotonic dystrophy kinase-related CDC42-binding kinase a 
NEK3 NIMA (never in mitosis gene a)-related kinase 3 
p70S6K p70S6 kinase 
p70S6Kb p70S6 kinase b 
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 
PDHK1 Pyruvate dehydrogenase kinase isozyme 1 
PKB$ Protein kinase B $ 
PKB# Protein kinase B # 
PKB! Protein kinase B ! 
PKC$ Protein kinase C $ 
PKC( Protein kinase C ( 
PKCeta Protein kinase C eta 
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PKCiota Protein kinase C iota 
PKCtheta Protein kinase C theta 
PKD3 Protein kinase D3 
PKG1/cGKI cGMP-dependent protein kinase 1 
PLK1 Polo-like kinase 1 
PLK2 Polo-like kinase 2 
PLK4 Polo-like kinase 4 
RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 
RSK1 Ribosomal S6 kinase 1 
RSK2 Ribosomal S6 kinase 2 
RSK3 Ribosomal S6 kinase 3 
RSK4 Ribosomal S6 kinase 4 
 
In summary we have here shown that upon interaction with human DCs, Mtb induces 
an immune response biased towards induction of Th17 with concurrent lack of Th1-
induction, suggesting oppositely directed regulations. Certain Mtb-specific kinases 
were identified that could be involved in this regulation, but further cell culture test-
ing is needed to validate the role of the individual kinases.  
 
4.4 Method summary 
CD1a-high monocyte-derived DCs were isolated as described by Søndergaard et al. 
(J. Immunol. Method., submitted 2012), and stimulated with Mtb or LPS for 30 min, 
6 hours, and 24 hours for kinome-, T cell co-culture- and phenotype-analysis, respec-
tively. DCs and T cells were subsequently co-cultured for 6 days. Phenotype of DCs 
and T cells were analyzed by flow cytometry and ELISA. For kinome analysis, DCs 
were lysed in a modified RIPA buffer. Proteins were precipitated, denatured, reduced 
and alkylated before being digested with LysC and trypsin. Peptides from unstimulat-
ed, LPS- and Mtb-stimulated DCs were differentially labelled on SepPack columns by 
dimethyl labelling,207 and subsequently mixed together. Phosphopeptides were en-
riched by TiO2-based enrichment, and analyzed by LC-MS/MS on a Q Exactive 
(Thermo Scientific). Spectral matching was conducted using MaxQuant (version 
1.2.2.5). Statistical analysis of MS data was done using R (version 2.15) and Python 
(version 2.6) and was based on normalized ratios of regulated peptides. All peptides 
with a regulation value larger than one SD from the mean were used for predicting 
kinase activity modulations using NetworKIN (version 2.0). Data was visualized by 
Cytoscape (version 2.8). 
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4.5 Methods 
Reagents. The following reagents was obtained through the NIH Biodefense and 
Emerging Infections Research Resources Repository, NIAID, NIH: Mtb, strain 
H37Rv, !-irradiated whole cells, NR-14819. E. coli LPS (026:B6) was purchased 
from Sigma Aldrich. The following anti-human Abs were used in the studies: 
CD1a/PE (clone# HI149), HLA-DR/v500 (G46-6), CD86/v450 (2331(FUN-1)), PD-
L1/PE-Cy7 (M1H1), MR/APC (19.2), CCR2/AF647 (48607), CCR5/APC-Cy7 
(2D7/CCR5), DC-SIGN/FITC (DCN46), IL17A/PE (SCPL1362), IFN-!/v500 (B27) 
(all from BD Biosciences), CCR7/APC-eFlour780 (3D12), (eBioscience), 
CD16/FITC (3G8), and CD40/PerCP-Cy5.5 (5C3) (both from Biolegend).  
 
Human blood samples. Human buffy coats were acquired from the blood bank at the 
Copenhagen University Hospital (Rigshospitalet) collected from anonymous healthy 
donors. Blood samples were handled in accordance with guidelines put forward in the 
“Transfusion Medicine Standards” by the Danish Society for Clinical Immunology 
(www.dski.dk). The buffy coats were obtained from 450 mL whole blood donations 
in citrate phosphate dextrose anticoagulant. The whole blood was fractionated to sep-
arate the majority of erythrocytes and plasma. The buffy coat contains approximately 
90% of the leukocytes from the 450 mL of blood, and was used within 5.5 hours upon 
blood draw. 
 
Cell purification and culture. PBMCs were isolated from human buffy coats by Fi-
coll-Paque (GE Healthcare) density centrifugation. The PBMCs were labeled with 
magnetic-particle linked CD14 Abs and isolated using MACS (Miltenyi). Cells were 
cultured in RPMI 1640 (Lonza) containing 2% (volume to volume) L-glutamine 
(Lonza), 10% fetal bovine serum (FBS, Lonza), 1% penicillin, streptomycin (Lonza), 
50 &M #-ME (Sigma-Aldrich) and 10 mM HEPES (Lonza). Cells were kept in a hu-
midified 37°C, 5% CO2 incubator. For differentiation of monocytes into immature 
DCs, the medium was supplied with 20 ng/mL ('160 U/mL) recombinant human 
GM-CSF and 30 ng/mL ('150 U/mL) recombinant human IL-4 (both CellGenix). The 
cells were grown in polystyrene 6 well plates (Nunc) at a concentration of 2*106/mL. 
Monocyte cultures were supplied with fresh medium containing fresh GM-CSF and 
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IL-4 on day 3. Non-adherent immature DCs were harvested on day 6, and enriched 
for CD1a-hi expression by MACS as previously described (Søndergaard et al., J. Im-
munol. Method., submitted 2012). CD1a-hi enriched DCs were plated at a cell con-
centration of 106/mL and stimulated with 500 ng/mL LPS and 500 &g/mL Mtb (final 
concentrations) determined as optimal concentrations in dose-response experiments 
(data not shown). Right before adding Mtb, clumps of bacteria was disrupted through 
syringe shearing by passing the solution 10 times through continuously smaller nee-
dles in the order 18-, 21-, 23-, 25- and 27-gauge.  
 
CD4+ naïve T cell co-culture. PBMCs were enriched for CD3+ cells by Dynabeads 
FlowComp human CD3-kit (Invitrogen), which enables removal of magnetic labeled 
Abs before cell sorting. Subsequently CD3-enriched PBMCs were labeled with anti-
bodies against CD4/ECD and CD45RA/APC and sorted on MoFlo XDP (Beckman 
Coulter) according to CD4+CD45RA++. Purity of T cells were assayed on 
FACSCanto II, and were >97% for all donors. Prior to the co-culture DCs were stimu-
lated with the respective stimuli for 6 hours. DCs were washed, counted, and added in 
a ratio of 1:20 to naïve T cells. T cells and DCs were co-cultured for 6 days. Superna-
tants were harvested, and T cells were re-stimulated with 10 ng/mL phorbol 12-
myristate 13-acetate (PMA) (Sigma Aldrich) and 1 &g/mL ionomycin (Sigma Al-
drich) for 6 hours. After 1 hour 10 &g/mL brefeldin A (BD Biosciences) was added.  
 
ELISA. ELISA was performed according to the manufacturer’s instructions. Superna-
tants of stimulated and unstimulated DCs were harvested after 24 hours and kept at -
40°C until analysis. The following ELISA kits were used in this study: human IL-1#, 
IL-6, IL-10, IL-17, IL-12, IL-27, IFN-! (all R&D Systems) and IL-23p19p40 (eBio-
science). 
 
Flow cytometry. Flow cytometry was performed according to standard procedures. 
The wash and staining buffer consisted of PBS with 1% FBS and 0.1% Na-azid (Sig-
ma-Aldrich). Before staining, the cells were incubated for 10 minutes in staining 
buffer with 2% allogeneic human AB plasma (Rigshospitalet) to limit non-specific 
binding of Abs. Intracellular flow cytometry was conducted as previously 
described.208 
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Quantitative real time PCR. DCs were stored in RNAprotect Cell Reagent (Qiagen) 
at -80°C until analysis. RNA was extracted and purified from DC preparations using 
the RNEasy plus micro kit (Qiagen). cDNA was generated using the high-capacity 
cDNA reverse transcriptase kit (Applied Biosystems). cDNA was quantified by quan-
titative real time PCR using TaqMan fast universal PCR master mix (Applied Biosys-
tems) with the primers and probes from inventoried TaqMan gene expression assay 
mixes for IL12A (cat# Hs00168405_m1), IL10 (Hs00174086_m1), GAPDH 
(Hs99999905_m1), and ACTB (#-actin, Hs99999903_m1). Amplification was ana-
lyzed on a 7900HT Fast RT-PCR system (Applied Biosystems). Relative quantity of 
IL12A was determined by using GAPDH as a housekeeping gene, and was similar to 
results obtained using ACTB (data not shown).  
 
Phosphoproteomics. 10 million CD1a-hi human monocyte-derived DCs were rested 
for 60 minutes in a humidified 37°C, 5% CO2 incubator before adding stimuli.  After 
30 minutes of stimulation, cells were quickly washed in 4°C PBS before being lysed 
in 2 mL of a modified RIPA buffer consisting of: 50 mM Tris (pH 7.5), 150 mM 
NaCl, 1% NP-40, 0.1% Na-deoxycholate, 1 mM EDTA, 5 mM #-glycerophosphate, 5 
mM NaF, 1mM Na-orthovanadate (all from Sigma Aldrich) and Roche complete pro-
tease inhibitor cocktail. Proteins were precipitated in 80% acetone (Sigma Aldrich) at 
-20°C overnight. The protein pellet was dissolved in 2 mL denaturation buffer con-
sisting of 6M urea, 2M thiourea and 10 mM HEPES (pH 8.0) (all from Sigma Al-
drich), and protein concentration measured using the Bradford assay (Pierce). Con-
centration was around 1 mg protein/5*106 DCs. After normalizing the protein-
concentration between samples, DTT (Sigma Aldrich) was added at 1 mM final con-
centration and incubated 60 minutes at room temperature. Subsequently proteins were 
alkylated using 5 mM (final) chloroacetamide (Sigma Aldrich) for 60 minutes at room 
temperature in the dark. Samples were next treated with 10 &g LysC (biochemical 
grade, Wako Bioproducts) for 4 hours at room temperature. Afterwards samples were 
diluted 4X in ultrapure H2O and adjusted to pH 8-8.5. 10 &g trypsin (modified se-
quencing grade, Promega) was added to each sample and incubated overnight at room 
temperature. Trypsination was stopped by adding trifluoroacetic acid (Sigma Aldrich) 
at a 2% final concentration, lowering the pH to about 2.5. The peptide mixture was 
centrifuged 5 min at 1800g to get rid of debris. Samples were dried down by vacuum 
centrifugation and reconstituted in 5% formic acid and differentially labeled by the 
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on-column dimethyl labeling method described in 207. This step included purification 
of peptides on a SepPak column (Waters). After labeling, samples from each donor 
were mixed and phosphopeptides enriched using TiO2-based enrichment. 1-1.3 mg 
TiO2 beads (GL Sciences) were added and incubated for 30 minutes on lab rotor at 
room temperature. Beads bound to phosphopeptides were spun down and supernatant 
were enriched for phosphopeptides with a second round of TiO2 beads. This step was 
repeated giving a total of 3 phosphopeptide-enriched fractions. Peptides were separat-
ed from the TiO2-beads by a C8 StageTip (Thermo Scientific), and the peptide mix-
ture was purified by a C18 StageTip (Thermo Scientific). LC-MS/MS was conducted 
on a Q Exactive (Thermo Scientific). Spectral matching was conducted using 
MaxQuant (version 1.2.2.5). Statistical analysis of MS data was done using R (ver-
sion 2.15) and Python (version 2.6) and was based on normalized ratios of regulated 
peptides. All peptides with a regulation value larger than one SD from the mean were 
used for predicting kinase activity modulations using NetworKIN (version 2.0). Data 
was visualized by Cytoscape (version 2.8). 
 
Statistics. All data was tested for a Gaussian distribution using a D’Agostino & Pear-
son omnibus test. Data that did not follow a Gaussian distribution were either log-
transformed or analyzed by a non-parametric statistical method. Statistical signifi-
cances were based on a student’s paired t-test, a repeated measures ANOVA with a 
Tukey post-hoc test, or a Friedman test with a Dunns post-hoc test. Analysis was con-
ducted using Prism 5 (Graphpad Software). 
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5 High-mannose glycosylation of HIV-1 gp120 and im-
mune regulation in human plasmacytoid dendritic cells  
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5.1 Abstract 
Background. Plasmacytoid dendritic cells (pDCs) play a vital role in activation of 
anti-HIV-1 immunity, and suppression of pDCs might mitigate early responses 
against HIV-1. HIV-1 gp120 high-mannose has been attributed immunosuppressive 
roles in human myeloid DCs. The present focus was to examine the role of HIV-1 
gp120 high-mannose on pDC immunity.  
Methods. Human peripheral blood pDCs were incubated with recombinant gp120s 
and an RNA analogue, or with inactivated or infectious HIV-1 strains. Intact HIV-1 
was enzymatically treated to perturb gp120-mannose display. IFN-$ production, 
CD40, CD86, HLA-DR, CCR7, PD-L1 expression levels and viability in pDCs were 
determined.  
Results. Recombinant gp120s induced various phenotypes in pDCs, and the manno-
sylation degree on attenuated HIV-1 correlated inversely with IFN-$ levels. However, 
perturbing the original mannosylation pattern on attenuated or viable HIV-1 strains 
failed to modulate viability, IFN-$, or surface marker expression in pDCs. In contrast, 
viable HIV-1 strains were found to confer differential, tropism-related effects on the 
pDC response, including profound cellular necrosis provoked by R5 strains. 
Conclusion. Mannosylation of gp120 on viable HIV-1 did not contribute to immune 
regulation of pDCs. Selected, viable R5-tropic HIV-1, however, mediated non-
mannose-dependent cellular atrophy of pDCs that might diminish innate immunity 
during early stage infection.  
 
  
5.2 Introduction 
Modulation of the human immune system by glycan-moieties from various pathogens 
is increasingly being recognized as a virulence factor. Particularly myeloid dendritic 
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cells (mDCs) have received much focus, and have been shown to be modulated by #-
glucans, fucose, and high-mannose residues.148 One of the most notorious pathogens 
of our time, HIV-1, is covered in a shell of glycan-moieties all linked to the mem-
brane-associated glycoprotein gp120.209–211 Recent data has indicated that a large part 
of these glycans consists of high-mannose,212 which is capable of binding C-type lec-
tin receptors (CLRs) present on DCs. Specifically, DC-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN) and the mannose receptor (MR) pre-
sent on mDCs has been shown to interact with gp120 high-mannose.213,214 Upon in-
teraction, immunosuppressive responses are taking place, therefore suggesting that 
HIV-1 uses high-mannose-CLR ligation for evasion of a productive immune response 
in DCs.148,149 
 
Plasmacytoid DCs (pDCs) are found in very scarce numbers in the human blood cir-
culation (0.2-0.5% of peripheral blood mononuclear cells (PBMCs)), but play an ut-
most important role in initiating immune responses against HIV-1.144,215 The main 
effector molecule produced by pDCs is IFN-$, which has been shown to limit HIV-1 
replication in CD4+ T cells.153 pDC-derived IFN-$ furthermore activate mDCs,140 and 
NK cells,151 and polarize naïve CD4+ T cells towards Th1.152 These three cell types 
are important for combating intracellular viral infections like HIV-1, underscoring the 
importance for pDCs during an HIV-1 infection. IFN-$ production from pDCs is ini-
tiated by triggering of TLR7 or TLR9, with the former being responsible for recogniz-
ing HIV-1 by virtue of its’ genomic ssRNA.141 pDCs also express the CLRs BDCA-2 
and DCIR,19,21 but currently the glycan molecular patterns recognized by these recep-
tors are unknown. DCIR has, however, been shown to bind HIV-1 most likely 
through gp120,216 and recombinant gp120 has been shown to ligate to a cell line trans-
fected with BDCA-2.147 Activation of BDCA-2 and DCIR by Ab-crosslinking has 
been shown to inhibit TLR9-mediated IFN-$ production in pDCs.19,21 Similarly re-
combinant gp120 has been shown to inhibit TLR9-mediated production of IFN-$,147 
but curiously no gp120-mediated inhibition in TLR7-triggered pDCs was observed in 
this study. This latter, and all other studies conducted on the immune-suppressive 
effect of HIV-1 high-mannose have used recombinant gp120. Different response 
types are demonstrated dependent on which gp120 was employed.149 An explanation 
for this was recently provided by Raska et al., reporting that the expression system 
used to produce the recombinant gp120 protein is greatly influencing the glycosyla-
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tion pattern on gp120.159 Therefore it is desirable to study the original mannosylation 
pattern on HIV-1 in order to make firm conclusions on the immune-regulatory abili-
ties of viral-exposed gp120.  
 
In this study we tested if human pDC immunity is modulated by high-mannose from a 
range of recombinant gp120s, AT-2 attenuated HIV-1 strains, and viable HIV-1 
strains. We show that by use of recombinant gp120s, some degree of regulation of 
TLR7-triggered pDCs is observed. On inactivated HIV-1 strains, a higher strain-
specific mannosylation of gp120 negatively correlated with the amount of IFN-$ pro-
duced. However, high-mannose perturbed complete viral particles did not induce any 
change in the pDC phenotypes, therefore suggesting that this virulence mechanism is 
not important in the interplay between human pDCs and HIV-1.  
 
5.3 Materials and Methods 
Reagents. The following reagents were obtained through the NIH AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH: IIIB (CHO-
derived), 96ZM651 (Sf9/baculovirus-derived) and BaL (HEK-293-derived). Aldrithi-
ol (AT)-2 inactivated HIV-1 strains BaL and MN and corresponding microvesicle 
controls217 were provided by the AIDS and Cancer Virus Program, SAIC Frederick 
Inc./National Cancer Institute supported with federal funds from the National Cancer 
Institute, National Institutes of Health, under contract HHSN261200800001E. R848 
and CpG ODN2216 were purchased from Invivogen. The following anti-human Abs 
were used in the studies: HLA-DR/v500 (clone# G46-6), CD86/v450 (2331(FUN-1)), 
PD-L1/PE-Cy7 (M1H1), CD80/PE (L307.4), MR/APC (19.2), $MR (19.2) (all from 
BD Biosciences), CCR7/APC-eFlour780 (3D12), (eBioscience), CD40/PerCP-Cy5.5 
(5C3) (Biolegend), BDCA-2/FITC/APC (AC144) (Miltenyi).  
 
Human blood samples. Human buffy coats were acquired from the blood bank at the 
Copenhagen University Hospital, Rigshospitalet (Copenhagen, Denmark) collected 
from anonymous healthy donors. Blood samples were handled in accordance with 
guidelines put forward in the “Transfusion Medicine Standards” by the Danish Socie-
ty for Clinical Immunology (www.dski.dk). The buffy coats were obtained from 450 
mL whole blood donations in citrate phosphate dextrose anticoagulant. The whole 
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blood was fractionated to separate the majority of erythrocytes and plasma. The buffy 
coat contains approximately 90% of the leukocytes from the 450 mL of blood, and 
was used within 5.5 hours upon blood draw. 
 
Cell purification and culture. Untouched human pDCs were isolated using the fol-
lowing three-step procedure: PBMCs were isolated from human buffy coats by Ficoll-
Paque (GE Healthcare). The PBMCs were enriched for peripheral blood DCs by the 
Dynal human DC enrichment kit (Invitrogen). Enriched peripheral blood DCs were 
purified for pDCs using the EasySep human pDC enrichment kit (Stemcell Technolo-
gies). Purities ranged from 95-98% assessed by BDCA-2 expression. Cells were cul-
tured in RPMI 1640 containing 2% (v/v) L-glutamine, 10% FBS, 1% penicil-
lin/streptomycin, 10 mM HEPES (all from Lonza), and 50 &M #-mercaptoethanol 
(Invitrogen). Cells were kept in a humidified 37°C, 5% CO2 incubator. Monocyte-
derived DCs were generated from CD14+ MACS-purified (Miltenyi) monocytes in 
culture medium supplied with 20 ng/mL recombinant human GM-CSF and 30 ng/mL 
recombinant human IL-4 (both CellGenix). Monocyte cultures were supplied with 
fresh GM-CSF and IL-4 on day 3, and non-adherent immature DCs were harvested on 
day 6.  pDCs were stimulated with normalized concentrations of HIV-1 either accord-
ing to p24 capsid concentration or according to multiplicity of infection (MOI). R848 
was added at 2.5 &g/mL, CpG ODN2216 at 5 &M, and blocking $MR Ab at 5 &g/mL 
(added 30 min prior to stimulations). 
 
HIV-1 culture. The following HIV-1 strains were used in these studies: BaL (R5), 
MN (X4), BX08 (R5), and NL4.3 (X4). HIV-1 strains were grown in donor PBMCs 
(Rigshospitalet) in RPMI 1640 containing 10% FBS, 1% penicillin/streptomycin and 
supplemented with recombinant human IL-2 (10 IU/mL) (Roche). Virus proliferation 
was measured by p24 ELISA218 and at peak viral concentration cell free virus super-
natants were harvested. Aliquots were stored at -80°C in order to limit differences 
between assays.  
 
p24 ELISA. p24 concentration in HIV-1 preparations was measured using an in-
house sandwich ELISA218 (Statens Serum Institut, Copenhagen, Denmark). The p24 
values obtained using this ELISA corresponded to the values determined for AT-2 
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HIV-1 strains by HPLC at the AIDS and Cancer Virus Program, SAIC Frederick, 
Inc./National Cancer Institute, Frederick. 
 
Copy-number determination. Viral RNA was extracted using the QIAamp viral 
RNA mini kit (Qiagen). Purified RNA and HIV-1 RNA standards were quantified by 
quantitative real time reverse transcription PCR using Superscript III system with 
Platinum Taq DNA Polymerase (Invitrogen). Primers and probes are described else-
where.219,220 Amplification was analyzed on an Mx3005P QPCR system (Agilent 
Technologies).  
 
IFN-"2a ELISA. Supernatants from pDCs stimulated with viable HIV-1 were inacti-
vated using Triton X-100 (Sigma Aldrich) at a final concentration of 1%. IFN-$2a 
was measured using a human tissue culture kit on a Sector Imager 2400 (both Meso 
Scale Discovery). 
 
Flow cytometry. Flow cytometry was performed according to standard procedures 
using a FACSCanto II or a LSR II (both BD Biosciences). The wash and staining 
buffer consisted of PBS with 1% FBS and 0.1% Na-azid (Sigma-Aldrich). Before 
staining, the cells were incubated for 10 minutes in staining buffer with 2% allogeneic 
human AB plasma (Rigshospitalet) to limit non-specific binding of Abs. pDCs stimu-
lated with viable HIV-1 were fixed in 2% paraformaldehyde (Polysciences) prior to 
acquisition of data. Viability of pDCs was measured using a LIVE/DEAD fixable 
dead cell stain kit with a near infrared fluorescent reactive dye (Invitrogen). FACS 
data was analyzed using FlowJo (Treestar).  
 
Western Blot. HIV-1 preparations were lysed in RIPA buffer containing a protease-
inhibitor cocktail (both Cell Signaling Technology). Proteins were loaded normalized 
according to p24 capsid concentration and separated under reducing conditions by 
SDS-PAGE in MOPS buffer (Invitrogen). Immobilon-P PVDF membrane (Millipore) 
was blocked for 1 hour at room temperature in Pierce Superblock with tween-20. 
Primary gp120 Ab (Abcam cat# ab21179) was incubated overnight at 4°C (1:2000 
dilution in superblock), and secondary Ab-HRP (Abcam cat# ab6741) was incubated 
for 45 min at room temperature on rocker (1:20,000 dilution in superblock). HRP-
conjugated high-mannose-specific lectin from G. nivalis (EY Laboratories) was incu-
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bated overnight at 4°C (1:20,000 dilution in superblock). Protein/mannose bands were 
visualized using an ECL+ kit (GE Healthcare) and a G:BOX CCD camera (Syngene). 
Intensity of bands was determined by Genepix Pro software (Molecular Devices).  
 
Enzymatic removal of high-mannose from HIV-1 strains. AT-2 inactivated and 
viable HIV-1 strains were mixed with 5X Endoglycosidase (Endo) H reaction buffer 
(250 mM sodium phosphate buffer, pH 5.5, Sigma Aldrich) and added either Endo H 
to a final concentration of 0.2 units/mL or vehicle control consisting of 20 mM Tris 
HCl, pH 7.5, with 25 mM NaCl and incubated at 37°C for 1 hour. Initially a time 
study was conducted to determine the optimal incubation time for the enzyme (Fig. 
S1). Endo H and free mannose-units were subsequently removed using Amicon ultra 
0.5 centrifugal units with a 50 kDa cut-off (Millipore). After processing p24 concen-
tration was re-assayed. 
 
 
Figure S1: Endoglycosidase H time-course. AT-2 (aldrithiol-2) inactivated HIV-1 BaL was treated 
with Endoglycosidase H (Endo H) or vehicle control for the indicated times. Afterwards preparations 
were lysed and loaded onto a SDS-PAGE gel. Proteins were separated under reducing conditions and 
blotted onto a PVDF membrane. A polyclonal gp120-Ab (gp120) was used to determine the gp120 
levels, and G. nivalis lectin to detect the presence of high-mannose structures on gp120. 
 
 
Statistics. Statistical analysis was done by a Mann-Whitney, or a Wilcoxon matched-
pairs signed rank test for comparison of two variables, and by a Kruskal-Wallis test 
with a Dunns’ post-hoc test for comparison of more than two variables. Analysis was 
done using Prism 5 (Graphpad Software). 
 
 
All wells contains 50 ng p24
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5.4 Results 
HIV-1 recombinant gp120s diversely modulate pDC immunity 
Because of recent reports describing that the glycosylation pattern on recombinant 
gp120 varies according to the expression system (Fig. 1A),159 we decided to re-
evaluate the conclusions  in a former report describing a lack of crosstalk between 
ssRNA-triggered TLR7 and HIV-1 gp120.147 As the concentration of monomeric 
gp120 may need to be very high in order to effectively trigger the receptors that natu-
ral trimeric gp120-gp41 complexes interact with (Fig. 1B), we titrated a range of dif-
ferent gp120s from 10-100 µg/mL added together with the TLR7-triggering ligand 
R848. In contrast to the former report,147 one of the three gp120s tested induced a 
strong modulation of TLR7-induced IFN-$ production when added at 100 &g/mL 
(96ZM651, Fig. 1C and E). 96ZM651 HIV-1 gp120 lead to approximately 80% re-
duction in the ssRNA (R848)-induced IFN-$ production, while IIIB and BaL gp120 
did not modify the R848-induced phenotype. None of the tested gp120s resulted in 
major regulation of a range of pDC surface markers (Fig. 1D and E). Most notably 
were a decrease in the co-stimulatory molecule CD40 by the IFN-$ modifying gp120 
(96ZM651), and an increase in another co-stimulatory molecule CD86 for the other 
two gp120s (Fig. 1E). The antigen-presenting molecule HLA-DR, the lymph node 
homing receptor CCR7,187 and PD-L1, which has been associated with T cell exhaus-
tion,221 were only minimally up- and down-regulated by the three gp120s (Fig. 1E). It 
has previously been reported that MR is not expressed on pDCs, but here we observed 
that it was upregulated upon TLR7-triggering (Fig. 1F), thereby suggesting a possibly 
role for MR in high-mannose-induced modification of IFN-$ production in pDCs. In 
comparison to the classically MR-expressing monocyte-derived DCs, the level of ex-
pression on pDCs was, however, on average 5.1-fold lower. DC-SIGN, another man-
nose-binding receptor, was not induced on activated pDCs (data not shown). 
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Figure 1: Phenotypic modulation of TLR7-triggered human pDCs by recombinant HIV-1 
gp120s. A) Schematic representation of different glycosylation patterns found on recombinant 
gp120.159 B) Schematic representation of the difference between monomeric recombinant gp120 and 
natural trimeric gp120 held together by non-covalent attachment to three transmembrane gp41 units.222 
C-E) Human pDCs were stimulated for 16 hours with R848 alone (TLR7-triggering ssRNA analogue) 
or in combination with three recombinant gp120s, derived from different HIV-1 strains (BaL, 
96ZM651 and IIIB). After 16 hours, pDCs were analyzed for IFN-$ production by ELISA (C and E), 
and surface marker expression by flow cytometry (D-E). C-D shows representative data from one do-
nor, and E shows the average of all donors (n = 3-9, error bars are based on SD). E displays the % 
change induced by the three gp120s when added simultaneously with R848 as compared to R848 sin-
gle stimulation. F) Representative flow cytometry histograms for Mannose Receptor (MR) expression 
on unstimulated and R848-activated pDCs compared to monocyte-derived DCs (moDCs) (n = 10). 
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Statistical analysis was done by a Mann-Whitney test (in C), and a Wilcoxon matched-pairs signed 
rank test (in E), **p<0.01. GlcNAc: N-Acetylglucosamine, Man: mannose, NeuAc: N-
acetylneuraminic acid, Gal: galactose, Fuc: fucose.  
 
 
HIV-1 gp120 mannosylation inversely correlates with IFN-" production by hu-
man pDCs 
Given the results showing that pDCs can be modulated by at least one specific gp120, 
we decided to test whether this could be replicated when using complete HIV-1 parti-
cles. The mannosylation pattern of attenuated HIV-1 strains was analyzed by lectin-
specific Western blot (Fig. 2A-B, where GNL indicates the degree of mannose on 
gp120). For co-culture studies with pDCs, two different HIV-1 strains with very dif-
ferent degree of mannosylation were employed (BaL and MN) (Fig. 2A-B). Upon 
stimulation of pDCs with these two HIV-1 strains, it was apparent that the HIV-1 
strain with less gp120 mannose (MN) was able to activate the pDCs more profoundly 
than the strain (BaL) displaying more gp120-mannose (Fig. 2C-D). The most notable 
difference was seen at the level of IFN-$ production, with an average 2.9-fold higher 
IFN-$ production for MN (Fig. 2C). Small differences between MN and BaL were 
also seen in the level of expression of pDC activation markers (Fig. 2D). Notably, 
PD-L1 and CCR7 were expressed at a 1.3-fold and 1.8-fold higher level, respectively, 
upon activation with MN (less mannosylated) as compared to BaL. Likewise, MN 
also induced slightly higher levels of expression of the co-stimulatory molecules 
CD80, CD86 and CD40 than the HIV-1 strain with most mannose, while HLA-DR 
was upregulated to the same level by both strains (Fig. 2D).  
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Figure 2: Maturation of pDCs with attenuated HIV-1 strains that are differentially mannosylat-
ed. A-B) Western blot analysis of AT-2 inactivated HIV-1 strains. gp120 was used as loading control, 
and mannosylation levels were visualized by the mannose specific lectin G. nivalis lectin (GNL). B 
shows the ratio between intensity of GNL and gp120 bands and is representative for 2 independent 
experiments. C-D) The phenotype of HIV-1 stimulated pDCs as measured by ELISA (C) and flow 
cytometry (D). Microvesicle controls (Mv) were included as a control for contaminating cellular pro-
teins.217 Statistical analysis was done by a Wilcoxon matched-pairs signed rank test, *p<0.05, 
**p<0.01, ***p<0.001. Error bars represent SD.  
 
Perturbation of high-mannose on attenuated HIV-1 does not alter the pDC phe-
notype 
To directly examine if the degree of high-mannose on HIV-1 gp120 plays a part in the 
level of IFN-$ production in human pDCs, we enzymatically treated the HIV-1 strains 
to remove the high-mannose. A schematic representation of the cleavage site for the 
enzyme used to cleave of high mannose, Endo H, can be seen in Fig. 3A. Subsequent-
ly we tested the removal by lectin-specific Western blot (Fig. 3B-C). After Endo H 
treatment there was a visible perturbation of the high-mannose, seen by the lower 
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intensity of the GNL band after treatment, and by the band shift of the gp120 after 
mannose removal (Fig. 3B-C). The influence of high-mannose perturbation of gp120 
on the HIV-1 strains was determined based on regulation of the functional phenotype 
in pDCs (Fig. 3D-E). Surprisingly, we noticed that there was no differences in the 
phenotypes, indicating that the gp120-mannose might not play the role we assumed, 
and which it has also been attributed in the literature.147,148 This suggested that MR 
might not be involved in gp120-high mannose-mediated suppression of IFN-$ pro-
duction in pDCs, although the level of regulation of MR by ssRNA (Fig. 1F) and 
HIV-1 (Fig. 4A) infers a possible role. To further examine the involvement of MR, 
we therefore tested if blocking of the MR would affect IFN-$ production upon 
ssRNA/HIV-1 stimulation. Blocking the MR resulted in no significant differences in 
the pDC response (Fig. 4B).   
 
 
Figure 3: Removal of high mannose on AT-2 HIV-1 strains and the effect on pDC phenotype. A) 
Schematic representation of the cleavage site for Endoglycosidase H (Endo H). B-C) AT-2 inactivated 
HIV-1 strains were treated with Endo H or vehicle control, followed by removal of freed high-mannose 
and remainder of enzyme by spin columns. Western blot analysis was used to verify efficiency of the 
procedure. The ratio between intensity of GNL and gp120 bands were calculated and plotted in C), and 
are representative for 2 independent experiments. D-E) The phenotype of pDCs stimulated with high-
mannose perturbed HIV-1 strains for 16 hours. IFN-$ production was determined by ELISA and sur-
face markers by flow cytometry. Flow cytometry histograms in E are representative for all donors. The 
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value next to the histogram is the MFI value for the different surface markers. Each dot represents the 
mean of duplicates from one donor (n = 4, error bars = SD). Differences between high-mannose per-
turbed HIV-1 strains and unperturbed control strains were tested using a Wilcoxon matched-pairs 
signed rank test.  
 
 
Figure 4: HIV-1 mediated upregulation of MR in pDCs and the effect of MR blocking. A) pDCs 
were stimulated with AT-2 inactivated HIV-1 strains or microvesicle (Mv) controls for 16 hours, and 
analyzed for Mannose Receptor (MR) expression by flow cytometry. Monocyte-derived DCs (moDCs) 
stimulated with R848 was added as a positive control. B) pDCs were pre-incubated with anti-MR Ab 
or vehicle control for 30 minutes prior to addition of HIV-1 or R848 for 16 hours. IFN-$ production 
was subsequently analyzed by ELISA. Statistical analysis was done by a Mann-Whitney test, and error 
bars are SD. Data represents 2-6 donors.  
 
Viable HIV-1 strains induce variable pDC responses, but are unaffected by 
gp120 high-mannose 
Before finally excluding high-mannose from playing a role in pDC immunity, we 
sought to analyze if we could replicate the results obtained for attenuated HIV-1 
strains with viable HIV-1 strains. The mannose was removed on 4 different viable 
HIV-1 strains: BaL, MN, BX08 and NL4-3 (Fig. 5A), and subsequently used to 
stimulate pDCs. Intriguingly the pDCs responded very differently to the 4 strains. 
Two of the strains (BaL and BX08) induced a dose-dependent necrosis in pDCs, hav-
ing completely eradicated the pDCs at MOI 1 (Fig. 5B) irrespectively of the presence 
of gp120-mannose or not. The other two HIV-1 strains (MN and NL4-3) did not 
propagate more necrosis than unstimulated cells, and NL4-3 even increased the sur-
vival of pDCs. MN and NL4-3 upregulated surface markers on pDCs in a gp120-
mannose independent manner (Fig. 5D), but surprisingly, NL4-3 did not mediate IFN-
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$ production even at a very high MOI (MOI 2,500) (Fig. 5C). The IFN-$ production 
induced by viable MN was not modified by gp120-mannose perturbation (Fig. 5C), 
confirming our findings from gp120-mannose removal of the attenuated HIV-1 
strains.   
 
 
Figure 5: pDC response patterns to viable HIV-1 and effect of mannose perturbation. A) Western 
blot analysis of mannosylation degree on viable HIV-1 strains with and without Endo H-treatment. B-
D) Phenotype of pDCs stimulated with high-mannose-perturbed (Endo H) and unperturbed (vehicle) 
viable HIV-1 strains. B) The percentage of necrotic pDCs (brightest population) was measured using a 
viability dye (near infrared (nIR) LIVE/DEAD stain). The percentage of cells falling within the dead 
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cell gate (not shown) is given above each dot plot. C) IFN-$ production as measured by ELISA. D) 
Representative flow cytometry histograms from one donor. The data is representative for 3-7 donors. 
Statistical analysis was done by a Kruskal-Wallis test with a Dunns’ post-hoc test, and error bars are 
SD, ***p<0.001.  
 
High-mannose perturbed attenuated HIV-1 strains does not modulate a TLR-
triggered pDC phenotype 
Since we initially found that one recombinant gp120 were able to modify IFN-$ pro-
duction in TLR7-triggered pDCs, and others have shown the same for TLR9-triggered 
pDCs,147 we finally tested whether the removal of high-mannose could affect these 
TLR-responses (Fig. 6). Remarkably, comparisons of the effects of high-mannose 
containing, and non-containing inactivated HIV-1 on TLR7 or TLR9-triggered pDC 
responses revealed that HIV-1 did not induce any change at all of the TLR-induced 
response; not even additive.  
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Figure 6: The effect of high-mannose perturbed HIV-1 strains on the phenotype of TLR-
activated pDCs. Human pDCs were stimulated with R848 or CpG (TLR7 and TLR9 ligand, respec-
tively) alone or together with high-mannose perturbed inactivated HIV-1 strains (Endo H) or unper-
turbed control strains (vehicle) for 16 hours. Afterwards pDCs were analyzed for surface marker ex-
pression by flow cytometry and IFN-$ production by ELISA. The fold change in phenotype that was 
mediated by addition of HIV-1 strains to TLR7 (A) and TLR9 (B) activated pDCs is illustrated in the 
spider-web plots. The numbers on the y-axis denominates the fold change. Fold change was calculated 
for each donor separately and the average plotted on the graphs. Data are representative of two inde-
pendent experiments. 
 
5.5 Discussion 
HIV-1 gp120 high-mannose has been shown to modify immune responses in mDCs, 
but the role on pDC immunity has not been thoroughly investigated. Former experi-
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mental systems have consisted of recombinant gp120, which may not be glycosylated 
similarly to in vivo viral particles. Here we have used perturbed complete viral parti-
cles to demonstrate that HIV-1 gp120 high-mannose does not modulate immunity in 
human pDCs.   
 
Similar to a previous study in monocyte-derived DCs,149 we observed various regula-
tory potentials of different recombinant gp120s. Only one of three gp120s gave a sig-
nificant decrease in IFN-$ production, and only when added in a very high concentra-
tion of 100 &g/mL. When using complete viral particles mannosylated at different 
levels, it appeared that the mannosylation of the HIV-1 strains correlated inversely 
with the amount of IFN-$ produced. However, upon perturbation of the mannosyla-
tion on each strain it was evident that the difference in IFN-$ was independent on the 
level of gp120-mannosylation. Instead the varying levels of IFN-$ in pDCs exposed 
to inactivated MN and BaL might be explained by the difference in tropism between 
the two HIV-1 strains. In our studies, we have used two CCR5 (R5)-tropic HIV-1 
strains: BaL and BX08, and two X4 strains: MN and NL4-3. Collectively, the R5 
strains induced more necrosis and less IFN-$ compared to the X4 strains. One expla-
nation for the difference might be found in the route of entrance used by the different 
strains. HIV-1 is reported to enter immune cells either via direct fusion with the plas-
ma membrane or by receptor-mediated endocytosis.141 Fusion is the process that may 
lead to effective infection and takes place when HIV-1 interacts with CD4 and a co-
receptor on the host immune cell. Receptor-mediated endocytosis on the other hand 
leads to degradation of the virus inside acidified endolysosomes. In a report seeking 
out whether HIV-1 used endocytosis or fusion for the activation of pDCs, it was 
found that the employed X4 strain almost exclusively used endocytosis.141 In another 
study focusing on infection, it was shown that pDCs were more susceptible to infec-
tion by R5 viruses compared to X4 viruses,223 thus suggesting that R5 viruses are 
more likely to enter pDCs via fusion. To complicate matters more it was also shown 
that after endocytosis, and dependent on which endosomal compartment TLR7 or 
TLR9 are triggered in, pDCs either produce type I IFNs (early endosomal compart-
ment) or increase co-stimulatory molecule expression (CD40, CD80, CD86) and pro-
duce inflammatory cytokines (late endosomal compartments).224 These data may ex-
plain why one of our viable X4 strains (NL4-3) did not induce IFN-$ while being 
efficient in mediating up-regulation of co-stimulatory molecules on pDCs.   
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When reviewing published studies in detail there are some noticeable differences in 
the pDC responses to R5 and X4 HIV-1 strains that appear similar to our present find-
ings. For instance, pDCs stimulated with the same amount of two HIV-1 strains as 
measured by p24 capsid, (MN vs. JRCSF140 and BaL vs. IIIB225) showed a reduced 
production of IFN-$ for the R5 as opposed to the X4 strains. In contrast to the R5 
strains used in our study, these R5 strains did not induce necrosis in the pDCs. The 
necrosis inducing effect may therefore depend on the given R5 strain, or by the cul-
ture system used to produce the virus. When HIV-1 is grown in culture it is bound to 
mutate, and perhaps some of these HIV-1 preparations have lost the ability to kill the 
pDCs. In fact, because of this dichotomy we cultivated one of our R5 strains (BX08) 
again and this preparation somehow lost the ability to kill the pDCs. But it did not 
acquire the ability to induce IFN-$, not even when added at MOI 25. To make sure 
that the medium composition was not influencing the killing of pDCs, we up-
concentrated the initial HIV-1 preparation and added fresh medium instead, but again 
we observed killing of 99% of the pDCs at MOI 1, hence implying that the R5-
induced cellular atrophy in pDCs was due to the virus per se. It has been shown that 
after an HIV-1 infection, pDCs disappear from peripheral circulation,226–228 reflecting 
that they might migrate to the draining lymph nodes229,230 or the spleen.231 Our present 
findings indicate that the pDC disappearance also could be due to R5-induced necro-
sis of pDCs at site of infection, possibly influencing systemic recruitment of pDCs. 
Small induction of pDC cell death has been demonstrated previously upon interaction 
between a cell line chronically infected with IIIB (X4) HIV-1 and PBMCs.154 The 
prior study did, however, not include R5 viruses, and our data are therefore the first to 
demonstrate an R5-mediated eradication of pDCs. As this observation may serve im-
portant in relation to in vivo combat of HIV-1 at initial stages of infection, we are cur-
rently undertaking analysis to study the mechanism behind the HIV-1-induced necro-
sis in greater details.  
 
In conclusion, our data exclude a role for high-mannose-mediated immune suppres-
sion of pDC by HIV-1. Explicit comparisons of viable R5 and X4 HIV-1 strains sug-
gest that R5 strains might impede pDC immunity by inducing cellular death in pDCs, 
thus expanding the avenue of evasion mechanisms exploited by HIV-1 on innate im-
munity.  
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6 Final discussion  
Mtb and HIV-1 have both evolved excellent ways to evade the immune system, in 
order to avoid clearance. Common for these pathogens is their early interaction with 
DCs, which, in a manner similar to the Butterfly Effect, could have major impact on 
how the immune response develops at later stages. A tiny wicked signal at the initial 
interaction could potentially propagate into a huge impact on the final outcome. The 
current Ph.D. thesis have demonstrated that this may be the case for both HIV-1 and 
Mtb. R5 HIV-1 strains usually found early in infection could be eliminating the pDCs, 
thereby inhibiting proper activation of mDCs, which might have a detrimental role in 
the establishment of the founder HIV-1 population. Likewise Mtb may evade IL-
12p70-mediated Th1 induction, by exploiting the plasticity of moDCs, and by induc-
ing a prototypic extracellular response against this intracellular bacterium. If the sig-
nals delivered by DCs are either lacking (HIV-1 example) or misdirecting (Mtb ex-
ample), the remaining immune cells will not be able to respond correctly in order to 
clear the infection.  
 
The motivation behind this thesis was to generate a better understanding of the inter-
action between human DCs and the latency-inducing pathogens: Mtb and HIV-1. 
Specifically the focus has been to elucidate how Mtb avoids IL-12p70 production in 
moDCs, and if HIV-1 gp120 high-mannose modulates the phenotype of pDCs. Prior 
to the initiation of this work, a paradigm was emerging on how these pathogens could 
avoid clearance from our bodies, by virtue of a glycan-mediated dampening of the 
ensuing immune response.148 Therefore, a special focus was given to this type of im-
mune evasion strategy in both cell types. In contrast to what was expected, major gly-
can-mediated changes were not observed. pDCs appeared to be unaffected by HIV-1 
mannosylation, and moDCs were only modulated to a small extend by the Mtb-
expressed glycolipid ManLAM. However, even though the glycan-mediated modula-
tions in moDCs were smaller than expected, they are most likely one of many im-
mune evasion strategies Mtb employs to avoid clearance from the body. After all, Mtb 
has been around for ages with the first observations dating back to 5000 years B.C.,232 
therefore enabling Mtb to develop many different immune evasion strategies over 
time.   
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MoDCs has been used for many years as an in vitro analogue to test response patterns 
of mDCs found in vivo. However, recently it was demonstrated that moDCs may play 
a role in vivo,115,176 and in particular interest for Mtb-infections, they have been shown 
to migrate into the lungs of mice.115 Furthermore, both CD1a+ and CD1a- mDCs has 
been described in the human lungs.111,114,174,175 Testing if moDCs have any physiolog-
ic relevance in humans is, however, almost impossible, which should be kept in mind 
when interpreting the data generated using this system. One of the interesting obser-
vations made during this thesis work is the diverse ability of different donors to gen-
erate CD1a-hi moDCs. In chapter 2, it was described how the percentage of CD1a-hi 
moDCs generated using the same exact culture conditions varied between donors in a 
normal-distributed manner. If these moDCs have an in vivo relevance in humans, this 
may be able to explain why different individuals have very different response patterns 
to mycobacteria. The capability to develop protective immunity against mycobacteria 
is irregularly distributed among human beings. Only 10% of Mtb infected individuals 
develop active TB, whereas the main population of infected people carry a latent in-
fection. The number of people able to resist Mtb infection is, naturally, not known. 
From cases of M. leprae infected individuals, it is known that this mycobacteria can 
cause two types of diseases in different persons; i) tuberculoid leprosy characterized 
by a IL-12p70-induced Th1 response, and ii) lepromateous leprosy characterized by a 
Th2 response.198,199 Of these, the Th1-mediated response type has shown to be the 
most effective immune response against M. leprae. The importance of the Th1-
response in keeping mycobacterial infections under control can also be seen from 
patients with Mendelian susceptibility to mycobacterial disease.68 The mutations pos-
sessed by these patients in one of the genes: IFNGR1, IFNGR2, STAT1, IL12B, and 
IL12BR1 are very rare and would not be able to explain why many mycobacteria-
infected individuals do not develop a protective Th1 response. Most likely more sub-
tle common genetic variations contributes to mycobacteria susceptibility,233 which 
may be apparent if examining more carefully the phenotypes of the immune cells in-
teracting with mycobacteria. By re-assaying the data presented in chapter 2, and com-
paring the phenotype of the entire pool of moDCs from the two extremes in CD1a-
expression, two types of immune responses may be presented (Fig. 6.1). It could 
therefore be speculated that a patient in the lower CD1a-hi range would develop ac-
tive TB and lepromateous leprosy more easily, because of the diminished production 
of IL-12 family cytokines. Likewise, a patient in the high range of CD1a-hi DCs 
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might be able to either clear an Mtb-infection or develop tuberculoid leprosy. If this 
holds true, given that the number of CD1a-hi DCs follows a Gaussian distribution, 
you might generally expect that more than 10% of Mtb-infected patients would de-
velop active TB. At the current stage it is, however, impossible to say how many 
CD1a-hi DCs are needed to develop protective immunity. But based on the available 
epidemiological TB data it seems plausible that a low number of CD1a-hi DCs are 
needed in the lung tissue to prevent active disease, while larger numbers are required 
to avert latent Mtb infection. 
 
 
Figure 6.1: Overview of the heterogeneous immune responses against Mtb. moDCs were stimulat-
ed with Mtb for 24 hours and analyzed for surface marker expression by flow cytometry, and secreted 
cytokines by ELISA. The percentage of CD1a-hi DCs were noted and used to separate the DCs and 
thereby the response patterns into two groups based on <50% CD1a-hi expressing DCs (n = 7, blue 
bubbles) or >80% CD1a-hi expressing (n = 6, green bubbles). Afterwards the collected MFI for all 
DCs were extracted and used for the visualization. The average of all donors were used to calculate the 
bubble size, which represents MFI or pg/mL. One axis represents protection against Mtb (reflecting 
reported data in literature), while the other axis represents possible active disease progression.  
 
Currently the immune response against Mtb is described as being dominated by 
Th1/Th17 cells without discriminating these responses. It can be speculated, that an 
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early Th17 response could mediate granuloma formation by recruiting the wrong type 
of immune cells (i.e. neutrophils), thereby shielding of infected macrophages from the 
right type of immune cells arriving later during infection. An early Th1 response 
might instead be able to eliminate all infected cells, and may therefore lead to eradica-
tion of the infection. Th1 responses are taking place during an Mtb-infection, but cur-
rently the time-frame for induction of this response is uncertain. In mice experiments 
employing three different mouse strains only one of the strains gave a robust Th1 re-
sponse, and this response was not seen until 30 days after infection,234 indicating that 
initially in infection the Th1 response may be absent. Indirect evidence for an initial 
Th17 response can also be seen from neutrophilic arrival at the site of infection very 
early after initiation.235 If an early Th1 response were taking place, it would most like-
ly be induced with help from !(T cells or other innate lymphocytes producing IFN-! 
necessary to boost IL-12p70 in DCs. So far no one has demonstrated the presence of 
!(T cells in the lungs at steady state, but in monkeys small numbers have been found 
in the BALF two weeks after vaccination with BCG.236 If the !(T cells are not present 
before infection, or if they do not come into contact with DCs in the lung, this im-
portant link for early Th1 development may be missing. The !(T cells could also pro-
duce IL-17A or IL-22 instead of IFN-! and in this scenario, IL-12p70 production 
from DCs would not be boosted either, as suggested from the data presented in chap-
ter 2.  
 
An important point that can be learned from the studies on the interaction between 
HIV-1 and pDCs is to take into account the complexity of different HIV-1 strains 
when conducting research. In future studies on HIV-1’s interaction with the immune 
system it would be advantageous to distinguish between HIV-1 strains found early in 
infection and the ones found in late stage-disease, in order to determine how HIV-1 
generates the all-important founder population. Even though it has been determined 
that in the most cases the founder population originates from R5 strains,124,125 it is still 
difficult to completely ensure that the specific HIV-1 strains isolated are the ones that 
actually initiate infection, due to the high mutation rate of HIV-1 strains. In the stud-
ies conducted in this thesis we used a strain that is considered an early HIV-1 strain. 
This strain (BX08) was isolated 8 months after seroconversion,237 which means that, 
even though the strain is considered an early strain, in reality the strain would have 
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had plenty of time to mutate. However, HIV-1 strains isolated as early as possible are 
still the ones most likely to resemble the founder strain, and they currently provide the 
best alternative as a model system. To examine the hypothesis about R5-mediated 
killing of pDCs early in infection an in vivo study in monkeys could be conducted. In 
these experiments, the dose of HIV-1 should be so low that only certain strains can 
initiate infection, which could give a clue about which strains it is that are able to 
generate the founder population.  
 
A different complexity that is also really hard to study is the kinases activated in DCs 
upon pathogen encounter. In this study a specific time point was selected for the ki-
nome analysis, even though the optimal experiment would be to do a time-course 
from approximately 10 sec to 60 min, since phosphorylation and de-phosphorylation 
is taking place very rapidly. The reason why a time-course was not done in these stud-
ies was that the number of cells available was too low to assay more than one time 
point in one donor at a time due to sensitivity restraints in MS-based phosphoprote-
omics. Over time the sensitivity of MS-based phosphoproteomics will most likely get 
better, making it possible to conduct a time study. It will be interesting to repeat the 
Mtb kinome experiments at a later point. 
 
A better understanding of how the immune system is diverted by HIV-1 and Mtb, 
may lead the way for new and better treatments. The most important effector mole-
cule produced by pDCs is IFN-$, which by itself may be fulfilling the role of activat-
ing mDCs and other immune cells. Therefore IFN-$ could be a treatment-possibility 
to induce immune activation early after HIV-1 infection. Of course it would be detri-
mental to the host to inject IFN-$ systemically, and a more targeted approach is need-
ed in order to make this feasible. It should be a strategy that induces the response al-
most immediately after infection, as it is currently believed that as soon as the founder 
HIV-1 population is there; it is too late for interventions. A targeted approach may 
also be useful for treating Mtb. The purpose here would be to target the alveolar DCs, 
or the monocytes that replenish the DC pool so they at immediate impact with Mtb 
would produce copies amounts of IL-12p70, and induce a more profound Th1 rather 
than Th17 response. The targeted strategy could aim at inhibiting some of the kinases 
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identified in this thesis to be uniquely activated by Mtb. Even if a successful strategy 
for diverting the immune response towards Th1 was found, the data from chapter 2 
might indicate that only a certain amount of people would respond. If a person were 
pre-encoded to have a lot of CD1a-lo DCs incapable of producing IL-12p70, a Th1-
driving drug would most likely not have a great effect. But these reflections need to 
be justified in future studies. 
 
Given that moDCs are currently used for immunotherapy in various cancers, the dif-
ferences in moDC response types between donors could have detrimental roles for the 
moDC preparations used in this setting. There is of course certain release criteria for 
moDCs used for clinical applications, for instance, one release criteria has been that 
>80% of the moDCs should express CD80 and CD86.238 Our current data questions 
whether this is a proper release control, as can be seen from figure 6.1, CD86 does not 
vary much between donors from either side of the CD1a-expression range. One could 
therefore speculate that the diminished effectiveness of these vaccines could be due to 
injection of DCs with a tolerogenic function against the pulsed tumor-Ags. Clinical 
protocols use a higher concentration of IL-4 and GM-CSF than we did, and human 
plasma instead of FBS. These factors could affect the amount of CD1a-hi moDCs 
generated. We did test if increasing the concentration of IL-4 and GM-CSF would 
modulate the ratio of CD1a-hi moDCs in a couple of donors, and interestingly it did 
not. However, different recombinant cytokines could also affect the CD1a-
development, and it was outside the scope of this thesis to fully test how these differ-
ent protocols affect the moDC phenotype.  
 
Even though the results presented in this thesis can help explain some of the interac-
tion between our immune system and HIV-1 or Mtb, we are still far from understand-
ing the grant complexity of the interactions taking place in vivo. Some of the unre-
solved questions waiting to be answered are listed here: 
• Does Mtb take advantage of moDC plasticity in vivo? 
• Can CD1a-distribution explain differences in responsiveness to mycobacteria 
in vivo? 
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• Are !(T cells, or perhaps innate lymphoid cells, inducing IFN-! at the site of 
Mtb infection for early enhancement of the DC response in vivo?  
• Does R5 HIV-1-induced pDC necrosis take place in vivo, and can this be the 
missing link to discrimination of HIV-1 tropism at the portal of entry? 
• How does R5 HIV-1 induce necrosis in pDCs, and can this be exploited for 
vaccine construction?   
• Could removal of CD1a-lo moDCs improve cancer immunotherapy? 
 
In conclusion, the data presented in this thesis clearly demonstrates how important it 
is to study the initial interaction between the immune system and pathogens. Instead 
of letting HIV-1 and Mtb use the Butterfly Effect for their advantage, we should our-
selves take advantage of this theory for treating these diseases. Making a drug that 
induces a small difference as soon as the pathogen is encountered, could divert the 
immune response into the correct direction and mean huge differences at the final 
stages. This could lead the way to eradication of one or both of these notorious patho-
gens: HIV-1 and Mtb, and result in a better life for a vast amount of people. 
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